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Abstract

EXAMINING THE ASSOCIATION OF MEDICATION COMPLEXITY WITH
HEALTH-RELATED QUALITY OF LIFE IN OLDER ADULTS RECEIVING
COMMUNITY-BASED LONG TERM SERVICES AND SUPPORTS
by
Claudia A. Beck
Adviser: Dr. Kathleen Nokes
While the complexity of a medication regimen is a concern for all individuals, it is of
significant concern for community-dwelling older adults who often require multiple
medications to treat chronic health problems. Health related quality of life (HRQoL) has
been identified as a key quality outcome measure when assessing care of older adults,
particularly those with long-term care needs. Although the use of multiple medications
has been widely explored in the literature, there is a paucity of data regarding the
combination of several medication-related factors (number of active medications,
therapeutic drug class, and medication regimen complexity) and HRQoL in older adults.
Wilson and Cleary's health-related quality of life conceptual model was the theoretical
framework used to guide this study. This secondary analysis examined the relationship
among the number of active medications, the number of therapeutic drug classes, and
medication regimen complexity and HRQoL in community-dwelling older adults (68%
Hispanic, 75% female) who were recent recipients of home and community-based
services (H&CBS). The subjects in this study (N =123) were enrolled in a large, multisite study (N=470) (R01-AG025524, PI, M. Naylor). Medication-related data were
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obtained from medical charts, counted to include the active number of medications as all
prescription and over the counter drugs (mean =9.3), and a therapeutic drug class tool
(mean =4.9) measured the number of distinct therapeutic drug classes included in a
medication regimen. Medication regimen complexity (mean = 20.6) was measured using
the Medication Regimen Complexity Index (MRCI). The Medical Outcomes Study Short
Form (MOS SF-12 v2) physical (PCS) and mental component scores (MCS) measured
HRQoL. After controlling for age, gender, education, race, ethnicity, marital status and
cognitive status, it was determined that the number of active medications (β coefficient .497, p=.012) was a key predictor of physical health-related quality of life, while
therapeutic drug class and medication regimen complexity were not associated with
either physical or mental health-related quality of life. The number of medications
impacts on physical health-related quality of life but the directionality of that relationship
is not clear; there were no significant effects on mental health-related-related quality of
life and medication-related variables.
Keywords: Older adults, active medications, therapeutic drug class, medication regimen
complexity, community-based long term services and supports.
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Chapter I
Research Objective
"What will this drug do for me?" asks the patient. "Well" replies the physician, "a
rigorous systematic review of randomized trials shows that etidonate will improve
measures in your bone density." "I'm not impressed," replies the patient, "unless
those stronger bones improve my quality of life" (Guyatt et al. 2007, p.1232).
Background of the study
Medications are often used to cure and alleviate disease, improve quality of life,
and lengthen life expectancy (Gelland, Grenard, & Marcum, 2011). The Institute of
Medicine (IOM) (2013) has identified health-related quality of life as a national priority
for older adults and it has emerged as an important and appropriate construct for older
recipients of long-term services and supports. Health-related quality of life highlights
aspects of the older adult's well-being affected by changes in their health status and the
quality of their health care. Health-related quality of life is an individual's perception of
the impact of a disease and its treatment on well being (Sousa & Kwok, 2006). Cella
(1995) described health-related quality of life as “the extent to which one’s usual or
expected physical, emotional and social well-being are affected by a medical condition or
its treatment” (p.73).
The World Health Organization (WHO) defines health as "a state of complete
physical, mental, and social well-being and not merely the absence of disease or
infirmity" (WHO, 1948). This conceptualization of health into physical, mental and
social components has strongly shaped general health frameworks for more than 60 years
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(Fryback, 2010). In alignment with the WHO's definition of health, the theoretical
framework of health-related quality of life is fundamentally based on a multidimensional
view of health that includes physical, psychological, social functioning and well-being
(Borglin, Jakobsson, Edberg, & Hallberg, 2005; Thompson, Zack, Krahn, Andresen, &
Barile, 2012). The central components of health-related quality of life are required for an
individual to meet the daily demands of life (Achat, Levine, Coakley, & Colditz, 1998)
and have become an important outcome measurement in public health as well as in
clinical research and practice (Moriarty, Zack, & Kobau, 2003). This is due in part to the
advancement in treatment options and technology, particularly in the areas of chronic
disease treatment and management in older adults (Chen, Li & Kochen, 2005).
As the leading causes of death shift from acute illness to chronic disease, healthrelated quality of life is a significant outcome measure when determining the impact and
effectiveness of clinical interventions and treatment including medications (Chenet al.,
2005; Cleary & Howell, 2007; Francic & Jiang, 2006; Walters, Munro, & Brazier, 2001).
This outcome is important because the goals of treatment in chronic disease is to improve
function, slow disease progression, and reduce suffering. The aim is to reduce the
negative impact on health-related quality of life arising from treatment in older adults
rather than to achieve a cure (Degl'Innocente et al., 2002; Williams, 2002). As
individuals age, there is a greater likelihood to experience multiple health symptoms such
as pain and fatigue. These health complaints are relevant to nursing care through early
assessment of health symptoms that potentially affect a decline in health-related quality
of life (Borglin et al.,2005; Zubritsky et al.,2012).
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At any given time four out of five American older adults will use multiple
prescription medications, over-the-counter drugs or dietary supplements with 40% taking
5 to 9 medications and 18% taking 10 or more medications within eight or more
therapeutic drug classes (Classen, Mann, Wu, & Tomita, 2004; Institute of Medicine
(IOM), 2006; Slone Survey, 2006). In the United States, approximately 10,000 people
turn age 65 every day and by 2030, approximately one out of every five Americans will
be aged 65 years and older (Centers for Disease Control and Prevention, [CDC], 2011).
As life expectancy continues to increase and more drugs become accessible to reduce the
effects of chronic illness, the utilization of prescription medications will also increase
(Masoodi, 2008) particularly in older adults living in the community.
Community-dwelling older adults are the largest consumers of medications today
with approximately 20% actively taking ten or more different medications at a given time
(LeCouteur, Ford, & McLachlan, 2010; Slone Survey, 2006; Steinman & Hanlon, 2010).
The use of ten or more medications can easily be reached by following clinical practice
guidelines for a small number of concurrent conditions such as diabetes, hypertension,
chronic obstructive pulmonary disease and osteoarthritis (Boyd, et al., 2005; Slone
Survey, 2006). Medication therapy is more complex in older adults due to age-associated
physiologic changes, multiple co-morbidities, having numerous providers, using more
than one filling pharmacy, multiple dosing frequencies (Elliot, O’Callaghan, Paul, &
George, 2013; Planton & Edlund, 2009) using several forms of medications, for example
tablets, inhalers or injections (Boparai & Korc-Grodzicki, 2011; Paquin et al., 2013).
The use of multiple medications, also known as polypharmacy, contributes to
lower adherence, greater risk of falls (Tinetti et al., 2014), adverse drug events, increased
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risk of medication errors, increased emergency room visits, hospitalizations, decline in
cognitive status and nursing home admissions all of which result in increased health care
costs (Boparai & Korc-Grodzicki, 2011; Francic & Jiang, 2006; Fulton & Allen, 2005;
Jyrkka, Enlund, Korhonen, Sulkava, & Hartikainen, 2009; IOM, 1999; Preskorn, et al.,
2005; Steinman & Hanlon, 2010). If medication-related problems were ranked as a
disease by cause of death, it would be estimated to be the fifth leading cause of death in
the United States, making medication management in older adults a significant concern
(Ballentine, 2008; Slabaugh et al., 2010).
Despite the use of multiple medications being a significant concern in older
adults, a commonly accepted definition or consistent cut-point for polypharmacy has yet
to be established (Hajjar, Cafierio, & Hanlon, 2007; Slabaugh, Maio, Templin &
Abouzaid, 2010). Although operational definitions of polypharmacy have varied
significantly and gaining consensus on the definition is still lacking, a range of three to
five drugs has been frequently used (Hanlon, Schmader, Ruby & Weinberger, 2001;
Jyrkka, Enlund, Korhonen, Sulkava, & Hartikainen, 2009). However variation is seen ,
for example, Preskorn et al. (2005) defined polypharmacy to literally mean taking two or
more prescription medications daily.
When evaluating polypharmacy, therapeutic drug classification is important to
consider because of the potential for increased adverse drug events to occur (Hajjar,
et al., 2007; Willson, Greer, & Weeks, 2014). A large national survey identified the most
commonly used prescriptions medications in community-dwelling older adults in the
cardiovascular, endocrine and antilipidemic drug classes (Kaufman, Kelly, Rosenberg,
Anderson, & Mitchell, 2002). A study conducted by Gurwitz et al. (2003) found 1523
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adverse drug events were associated with a wide range of different therapeutic drug
classes with cardiovascular drugs most frequently cited (26%) followed by antibiotics
(14.7%) and non-opioid analgesics (11.8%).
Along with the use of a wide range of therapeutic drug classes, older adults are
frequently prescribed medications in varying doses, frequencies and routes of
administration (Steinman, et al., 2006). As a result, the complexity of the medication
regimen increases as the number of medications increase (George, Phun, Bailey, Kong &
Stewart, 2004). The most frequent reasons for medication errors have been linked to the
characteristics of complexity of an individual's medication regimen (administration,
frequency of dosing, and symptoms prompting the need for medications) (George et al.,
2004). Medication regimen characteristics have had significant impact on patient
outcomes (Elliot, 2012; George, et al., 2004). A study by Wolf et al. (2011) found
increased medication regimen complexity led to significant intrusion in patients' daily
lives. Nurses can make a significant impact in reducing the effects of medication
complexity in older adults and are in a unique position to modify the adverse
consequences of complex medication regimens (Frazier, 2005; Liu, Manias, & Gerdtz,
2011).
Generally, the goals of medication therapy for older adults are to treat disease,
diminish pain and suffering, avert life-threatening complications due to chronic illness,
lengthen life expectancy and ultimately improve quality of life (Gelled, et al., 2011). To
accomplish these goals, benefits and risks of optimal medication therapy must be
balanced against health-related quality of life factors for older adults with chronic illness
requiring long-term care needs (Cleary & Howell, 2007). Nurses often evaluate the
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effectiveness of drug therapy through assessment of symptoms including physical or
biochemical markers of disease activity (Griffiths, Johnson, Piper, & Langdon, 2004).
These evaluation strategies however are not sufficient as they do not reflect the multiple
determinants of health that could be revealed through health-related quality of life
measurement (Degl'Innocenti et al., 2004).
An estimated six million older adults receive long term services and supports
(LTSS) in their own homes, assisted living facilities or nursing homes (Abbott, Bettger,
Hanlon, & Hirschman, 2012; Kaye, Harrington, & LaPlante, 2010). Older adults with
chronic illness often require long-term care and the number of older adults who will be in
need of long-term services and supports in the United States will more than double by
2030 (Knickman & Snell, 2002). A person in need of LTSS requires human assistance
with activities such as bathing, dressing or eating or may need assistance with preparing a
meal, shopping or using a telephone as a result of physical, mental, or emotional
problems (Agency for Healthcare Research & Quality, [AHRQ], 2001). A wide range of
services are offered and maintained over an extended period of time to people with
chronic health care needs and functional deficits (Reinhard, Kassner, & Houser, 2011).
Physical, functional and cognitive decline in combination with multiple co-morbidities
underscore the importance of assessing health-related quality of life of individuals in
LTSS (Zubritsky et al., 2012).
Statement of the Problem
Is there an association of the number of active medications, therapeutic drug class,
and medication regimen complexity with health-related quality of life in community-
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dwelling older adults receiving home and community-based long term services and
supports in Washington Heights between 2007 and 2008? By examining three variables
related to medication use, specifically the number of active medications, therapeutic drug
class and medication regimen complexity, this study tested whether specific medication
constructs were associated with health-related quality of life.
Definition of Terms
Active medications. Active medications were defined as the number of
medications a subject was taking and included both prescription and over the counter
medications. Active medications were measured according to the medication list in the
electronic health record at the date of enrollment (see Appendix A) on the Health Related
Quality of Life Chart Abstract Tool (Naylor, 2004).
Cognitive status. Any mental process that involves symbolic operations to
include perception, memory, creation of imagery, and thinking and also includes
awareness and judgment capacity (McGraw-Hill Concise Dictionary of Modern
Medicine, 2002) and was measured by the Mini Mental State Exam (MMSE) (Folstein,
Folstein, & McHugh, 1975). (see Appendix B).
Community-dwelling. Individuals who reside at home and are not in an assisted
living facility or nursing home (Ganz et al., 2006) and was measured by the organization
providing the home and community-based services (see Appendix C) (Naylor, 2004).
Health-related quality of life. Health related quality of life is a health-focused
quality of life concept that includes characteristics of quality of life impacting health to
include physical, mental and functional health and is viewed from the individual’s
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perception of their physical and mental health (McHorney, 1999; Zubritsky et al., 2012).
Health-related quality of life was measured by the Medical Outcomes Study Short Form
(SF12 - v2) (see Appendix D) which provides a physical component summary (PCS) and
a mental component summary (MCS) that measures self-reported physical and mental
health ratings (Ware, Kosinski, & Keller, 1995).
Long term services and supports (LTSS). LTSS is a broad range of supportive
services required by individuals who have reduced capacity for self-care as a result of
physical, cognitive or mental disability or illness (Reinhard et al., 2011). Admission into
an LTSS setting was measured by the classification (e.g. Home and Community-based
{H&CBS}, Assisted Living Facility {ALF}, or Nursing Home {NH}) of the organization
that enrolled the older adult (see Appendix C) in the Health Related Quality of Life Chart
Abstract Tool (Naylor, 2004).
Medication regimen complexity. Medication regimen complexity is
conceptually related, but not equal to the count of medications and takes into account
several aspects of medication regimens to include dosage form (e.g. tablet, liquid), dosing
frequency (e.g. once a day, twice a day), and additional directions (e.g. crush pill, take
with food) (George et al., 2012) and was measured by the Medication Regimen
Complexity Index (MRCI) (see Appendix E) (George et al., 2004).
Therapeutic drug class. Is the classification system of drugs into different
groups according to the organ or system on which they act and their therapeutic,
pharmacological and chemical properties (World Health Organization Collaborating
Center [WHOCC], 2011). Therapeutic drug class was measured by the number of distinct
therapeutic drug classes present in the active medication list as defined by the 12
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therapeutic drug classes (see Appendix F) categorized in Drug Facts & Comparisons
2013.
Delimitations
This study included adults who were:
1) enrolled in the primary study Health Related Quality of Life: Elders in Long Term
Care (R01AG025524-01A2, PI, M. Naylor) during 2007 and 2008.
2) age 60 years and older
3) recently (within 60 days) recipient of community-based LTSS in New York, N.Y.
Theoretical Rationale
Most experts strongly recommend the use of a multidimensional conceptual
model to guide the assessment of health-related quality of life (Ware, 1994; Wilson &
Cleary, 1995). Wilson and Cleary (1995) developed a conceptual model (see Figure 1) of
health-related quality of life that addresses patient outcomes that provided a linear
depiction linking five domains of physiological variables, symptom status, function,
general health perceptions, and health-related quality of life (Nokes et al., 2011; Wilson
& Cleary, 1995). Prior to this conceptualization, there was little research that explored the
relationship between clinical variables and measurement of the multidimensional concept
of health-related quality of life (Chen et al., 2005; Wilson & Cleary, 1995). The model
(see Figure 1.1) focuses on the relationships among several domains of health-related
quality of life including: a) biological function and physiological factors; b) symptom
status; c) functional status; d) general health perceptions; and e) overall quality of life.
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There are two additional factors included in this model: a) characteristics of the
individual, and b) characteristics of the environment which impact on all of the domains
(Wilson & Cleary, 1995).

Figure 1.1. Wilson and Cleary’s Health-related quality of life conceptual model.
Reproduced with permission from Wilson I.B., & Cleary, P.D. (1995). JAMA, 273, 5965. Copyright © (1995) American Medical Association. All rights reserved. (see
Permission Appendix L).
Individual characteristics can be defined as distinguishing traits of a human being
to include measures of age, gender, education, race, ethnicity, marital status and cognitive
status (Naylor, 2004; Wilson & Cleary, 1995). Environmental characteristics include
interaction with providers, characteristics of the service delivery system, and the
structural features of the physical environment. The characteristics of the individual and
the environment are overarching factors that affect all of the five domains of overall
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quality of life (Nokes, et al. 2000). For the purpose of this study individual characteristics
included age, gender, education, race, ethnicity, marital status and cognitive status.
The intent of the health-related quality of life model was to unite the biomedical
and social science paradigms to make the connection between the mind and body (Sousa
& Kwok, 2006; Wilson & Cleary, 1995). The biomedical paradigm’s focal point relates
to the causative and pathological factors with outcomes measured within the clinical
aspects of biological and physiologic domains (Wilson & Cleary, 1995). The social
science paradigm’s focal point relates to the domains of environment, functioning and
overall well-being with the outcomes measuring intricate behaviors and feelings (Wilson
& Cleary, 1995). The key goal of clinical care is to improve patient outcomes. Wilson
and Cleary’s (1995) conceptual model of health-related quality of life links what is
occurring on a biological, biomedical level to the impact on individual’s symptoms,
functional status, general health perceptions and overall quality of life.
Biological function centers on cells, organs and organ systems. Examples include:
a) diagnoses such as inflammatory bowel disease or small cell lung cancer; b) laboratory
values to include creatinine, blood urea nitrogen, glucose, and serum hemoglobin; c)
measures of physiological function to include pulmonary function tests and physical
examination findings such as splenomegaly or systolic ejection murmur; d) number and
types of medications; e) height and weight; and f) medical conditions (Naylor, 2004;
Wilson & Cleary, 1995). Medical conditions are often treated with medications and
biological function was measured by the total number of active medications, therapeutic
drug classes and medication regimen complexity (see Table 1.1) in this study since
medications may impact on disorders of different biological systems.

MEDICATION COMPLEXITY AND HRQOL

12

Wilson and Cleary’s (1995) conceptual model of health-related quality of life has
been useful in creating strategies and instruments that identify and measure variables
associated with health-related quality of life and hence provide the opportunity to
improve outcomes in this domain (Sousa & Kwok, 2006; Wilson & Cleary, 1995).
Wilson and Cleary recommended assessing overall quality of life with general measures
to determine how happy or satisfied a person is with their life as a whole (Sousa & Kwok,
2006). The Medical Outcomes Study Short Form (MOS SF-12 v2) (see Appendix D)
provides an example of how assessment of health-related quality of life has been
integrated as part of an overall health survey to measure and determine outcomes (Brazier
& Roberts, 2004; Borglin et al., 2005; Gandhi et al., 2001; Jones, Jones & Miller, 2004;
Larson, Schlundt, Patel, Beard, & Hargreaves, 2008; Montazeri et al., 2011; Sousa &
Williamson, 2003).
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Table 1.1
Conceptual-Theoretical-Empirical-Structure
Wilson and Cleary's
Health-related
quality of life
conceptual Model

Biological and
physiological
function

Theoretical Linkages

Active medications,
therapeutic drug
class and
medication regimen
complexity

Self reported
mental and
physical health
scores

Empirical Indicators

Number of active
medications,

Medical Outcomes
Study Short Form
(SF-12 v2) Mental
Component Score
(MCS) and
Physical
Component Score
(PCS)

Therapeutic Drug
Classification
Medication
Regimen
Complexity Index
tool (MRCI)

Health-related
quality of life

Characteristics
of the
individual

Age , gender,
education, race,
ethnicity,
marital status,
and cognitive
status
1)Medical
Record
Abstract Demographic
data
2) Mini Mental
State Exam
(MMSE)

Research questions and hypotheses
Research question 1. Is there an association between the number of active
medications and physical and mental health-related quality of life of older adults
receiving community-based LTSS before and after controlling for age, gender, education,
race, ethnicity, marital status and cognitive status?
H1a: The number of active medications will be associated with physical healthrelated quality of life in of older adults receiving community-based LTSS.
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H1b: The number of active medications will be associated with mental healthrelated quality of life in of older adults receiving community-based LTSS.
Research question 2. Is there an association between the number of therapeutic
drug class and physical and mental health-related quality of life of older adults receiving
community-based LTSS before and after controlling for age, gender, education, race,
ethnicity, marital status and cognitive status?
H2a: The number of therapeutic drug classes will be associated with physical
health-related quality of life in older adults receiving community-based LTSS.
H2b: The number of therapeutic drug class will be associated with mental healthrelated quality of life in older adults receiving community-based LTSS.
Research question 3. Is there an association between medication regimen
complexity and physical and mental health-related quality of life in older adults receiving
community-based LTSS before and after controlling for age, gender, education, race,
ethnicity, marital status and cognitive status?
H3a: Medication regimen complexity will be associated with physical healthrelated quality of life in older adults receiving community-based LTSS.
H3b: Medication regimen complexity will be associated with mental healthrelated quality of life in older adults receiving community-based LTSS.
Study Significance
This study contributes: (a) to understand medication effects on health-related
quality of life in a racially and ethnically diverse population of older adults, (b) to
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advance knowledge of medication regimen complexity assessment, and (c) to the body of
evidence in nursing science to improve health care health-related quality of life outcomes
for older adults. Medications are vital to treat many chronic illnesses and maintain health
and quality of life for older adults. However there are significant negative outcomes
related to medication use. There is emerging evidence that older adults with multiple comorbidities vary in the amount of value they place on health outcomes such as longer
survival and prevention of specific disease events and the risk of medication-related
adverse effects that they are willing to endure (Roth & Levy, 2005; Tinetti, Bogardus, &
Agostini, 2004). Many efforts to evaluate the quality of medication use focuses on highrisk drugs, appropriate management of chronic disease or a set of pre-determined quality
indicators of medications rather than the patient themselves (Cleary & Howell, 2007;
Roth, Weinberger & Campbell, 2009). Nurses can provide comprehensive assessment
and interventions to support older adults to safely and appropriately manage their
medication regimens that provide cost-effective care and improvement in their healthrelated quality of life (Marek & Antle, 2008).
Older adults, and in particular those adults who are non-English speaking, have
multiple co-morbidities, or cognitive impairments, are often excluded from evidencegenerating research (Classen et al., 2005; Tinetti, Bogardus, & Agostini, 2004). In
addition, the literature regarding health-related quality of life in community-dwelling
older adults as it relates to medications factors (number of active medications, therapeutic
drug class, and medication regimen complexity) is sparse. This study contributed to the
evidence regarding medication-related factors and health-related quality of life in a small
sample of predominately Hispanic older adults.
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Chapter II
Review of Literature
The purpose of this study was to examine the relationships of medication-related
factors (the number of active medications, the number of therapeutic drug classes, and
medication regimen complexity) with health-related quality of life in older adults
receiving home and community-based services (H&CBS). The following review of the
literature represents the evidence relevant to this research study, namely, health-related
quality of life, a health-related theoretical framework, health-related quality of life in
older adults and Hispanics, multiple medication use in older adults, therapeutic drug class
use, medication regimen complexity and health-related related quality of life and
medication use.
Health-related quality of life
According to the WHO definition of quality of life, health is considered to be an
important domain that contributes to the overall quality of life (Singh & Dixit, 2010). De
Haes and van Knippenberg (1985) noted that the study of quality of life as it relates to
health provides a greater understanding of a patient's response to a disease as well as to
prescribed treatments. To better address this issue, the concept of quality of life in the
context of health and illness is known as health-related quality of life. The term was
intended to focus on the impact of health, illness and treatment on quality of life (Ferrans,
Zerwic, Wilbur & Larson , 2005; Singh & Dixit, 2010). The concept of quality of life
was originally used in cancer treatment by nurses and physicians to explain the
distinction between the medical and technical components of care and other aspects of
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patient care (De Haes & van Knippenberg, 1985). When confronted with the suffering of
patients directly, they focused on paying more attention to supportive care or quality
versus the duration of survival.
In the last 30 years, assessment of health-related quality of life has become more
relevant in health care particularly in the realm of health and illness, with the patient
considered to be an active participant in their care and their choice of treatment options
(Ferrans, Zerwic, Wilbur & Larson, 2005). Research conducted on several chronic
diseases has emphasized the relevance of evaluating health-related quality of life as part
of clinical practice to determine the effects of medical and community-based
interventions (Mickle et al., 2011; Singh & Dixit, 2010). Corace and Endler (2003) noted
that assessment of health-related quality of life is significant for a number of reasons;
specifically to provide clinicians with information related to the impact of disease and
illness on an individual’s daily life, effects of treatments on their health-related quality of
life and the ability to evaluate and measure the effects of interventions on health-related
quality of life (Corace & Endler, 2003; Ferrans et al., 2005) from the patient's perspective
(Sousa & Kwok, 2006).
Theoretical Framework
Wilson and Cleary (1995) developed a conceptual model of health-related quality
of life to address patient outcomes. The model has been widely used in different
populations to include patients living with HIV/AIDS, Parkinson’s disease and cancer
(Chrischilles, Rubenstein, Voelker, Wallace, & Rodnittzky, 2002; Nokes et al., 2000,
2011; Sousa & Williamson, 2003). Considerable work has been done to develop self-

MEDICATION COMPLEXITY AND HRQOL

18

administered health-related quality of life measures that can be scored through the use of
subscales that encompass pertinent predictors. Archat et al. (1998) described the
fundamental elements of health-related quality of life as functional status, general health
and well-being, and proposed that these elements are required for a person to meet the
daily demands of life and therefore satisfy their needs and desires. This description of
health-related quality of life is compatible with the Medical Outcomes Study Short Form
-12 (SF-12) (MOS SF-12) which aims to measure functioning, well being and general
health status (Ware, Kosinski, & Keller, 1996).
The MOS SF-12 was used by Sousa & Williamson (2003) to study the
relationship between symptom status and health-related quality of life utilizing the
Wilson and Cleary conceptual model. The sample (n=99) included emergency room
patients with a diagnosis of gastrointestinal bleeding with a mean age of 57.8 years with
62.6% being male. The Short Form 12 (SF-12) physical component scores (PCS) and
mental component scores (MCS) were used to measure health-related quality of life along
with a 15-item symptom checklist developed and validated for that study at baseline and
one month follow-up. Regression analysis controlling for age, gender, hematocrit, and
co-morbidities was used to examine the relationship between symptom status and healthrelated quality of life. Results showed that baseline symptom status contributed 20.2%
(R²change =.202, p=0.001) of the variance explained in the baseline PCS score and
23.2% (R²change =.232, p= 0.001) at one month follow-up. Symptoms status also
explained variance in baseline and follow-up MCS scores (R²change =.098, p=0.001 and
R²change =.292, p=0.001, respectively). This research suggested that symptom status
was a key predictor to health-related quality of life.
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Health-related quality of life in older adults
Predictors of health-related quality of life may be identifiable in older adults. This
is of particular importance as the demographic profile in the United States shift towards
old age with greater longevity, as adults over the age of 65 years comprise a growing
proportion of the population with major use of health care (Walters, Munro, & Brazier,
2001). As a result of this shift assessing health-related quality of life in older adults has
become an increasingly important component to address (Hickey, Barker, McGee, &
O’Boyle, 2005). Older adults have a greater probability of having numerous comorbidities and multiple health complaints that are not curable, and therefore greatly
affect their health-related quality of life.
Similarly, Borglin et al. (2005) described how health complaints and selected
characteristics of age, gender, living situation, marital status and socio-economic status
predicted overall and health-related quality of life in older adults. The SF-12 was used to
measure health-related quality of life with women reporting lower health-related quality
of life. The SF-12 PCS mean (p=0.03) was 37.7 for females and 40.6 for male and a
Mental Component Score (MCS) mean (p=0.005) of 51 for females and 54 for males.
Self-reported health problems such as pain (p=0.001), mobility problems (p=0.001) and
fatigue (p=0.001) significantly predicted lower physical health related quality of life. The
findings indicate that many common health issues occurring at the same time can
negatively impact older adults' health-related quality of life and may interact with each
other rather than in isolation.
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In addition, when compared to the general population, health-related quality of
life in older adults can be a significant indicator of health status with prognostic
implications (Otero-Rodriquez et al., 2010). Otero-Rodriguez et al., (2010) examined
whether changes in health-related quality of life could predict ensuing mortality among a
Spanish population aged 60 and older. The findings demonstrated that changes in healthrelated quality of life are predictive of mortality in older adults. The significance of
decreased health-related quality of life in older adults should trigger awareness of a
worsening prognosis and an assessment of possible causes of decline.
To further advance the assessment of health-related quality of life in older adults,
Zubritsky et al. (2013) adapted the Wilson and Cleary model within the context of older
adults who require long term services and supports (LTSS). To create a more rigorous
model, functional status domain now includes cognition and LTSS use and behavior were
added to environmental characteristics. The adaptation of this evolving model is more
reflective and relevant to measure the characteristics of this population, particularly when
cure is not the expected outcome, but rather the management of symptoms, chronic
disease and cognitive decline (Zubritsky et al., 2013).
Health-related quality of life and Hispanics
While increased awareness of declining health-related quality of life is important
for all older adults, few studies have examined health-related quality of life by race and
ethnicity and most have focused on only one measure of health-related quality of life
(Chowdhury, Balluz, & Strine, 2008). Many psychometric measures for health-related
quality of life instruments were created utilizing ethnically homogeneous subjects,
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making the suitability of administrating them to more ethnically diverse samples
questionable (Corliss, Nicholas, & Nokes, 2001). Most attempts to adapt health-related
quality of life measures, particularly the Short Form-36 (SF-36), across diverse minority
groups have been through the utilization of language translation (Regidor, Barrio, de la
Fuente, Domingo, Rodriguez, & Alonso, 1999; Tann, 2005). Hispanics are comprised of
culturally diverse sub-groups which may influence views of illness and therefore,
responses to questions related to health-related quality of life (Gonzalez-Burchard et al.,
2005; Porter, Vijil, Unruh, Lora, & Lash, 2010).
In addition to being culturally diverse, Hispanics are the largest and fastestgrowing minority population in the United States today (U.S. Census Bureau, 2011). In
2010, there were 50.5 million Hispanics in the United States (US Census Bureau, 2011).
Hispanics comprised 16.3% of the population, and the largest Hispanic subgroup among
this population consisted of Mexicans (63%) The second largest group was Puerto Rican,
comprising 9.2%, Cubans account for 3.5% and Dominicans account for 2.8% of the total
Hispanic population in the United States (Ennis & Albert, 2010). Yet there is a scarcity of
data regarding health-related quality of life in minorities and in particular, in Hispanics
(Porter et al., 2010).
Porter et al., (2010) highlighted certain issues in data collection that impact
health-related quality of life results for Hispanics. For example one issue, item response
bias, describes bias due to extreme response style with responses tending to collect
toward the extreme choices. Population-based studies of health-related quality of life
among people in the United States have found that Hispanics are more apt to report fair to
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poor health-related quality of life when compared with whites (Zahran, Kobau, Moriarity,
Zack, Holt, & Donehoo, 2005).
Likewise, Hayes et al. (2011) examined disparities in health-related quality of life
among adults with self-reported coronary heart disease (CHD). Using data from the 2007
Behavioral Risk Factor Surveillance System, disparities in health-related quality of life
were examined using the unhealthy days measurements for adults who self-reported
coronary heart disease (6.1% of surveyed population). The study findings demonstrated
that Hispanics were more apt than non-Hispanic whites to report fair or poor health status
(Adjusted odds ratio[AOR], 1.5).
The literature regarding Hispanics and health-related quality of life measurement,
although limited in volume, highlights the importance of selecting instruments that use
unbiased terms that are culturally relevant to all Hispanic sub-groups. The sample for this
secondary analysis was primarily recruited from a community in which the U.S. Census
data reports that 71% are of Hispanic ethnicity (U.S Census, 2011).
Multiple medication use in older adults
Medication-related problems are common, expensive and often avoidable in older
adults and can lead to poor health outcomes (American Geriatric Society, 2012a).
Polypharmacy, the concurrent taking of many medications, has been well documented in
the United States (Fulton & Allen, 2005; Jyrkka et al., 2009) and can be a significant
concern for improving quality of care for older adults. Medication therapy in older adults
presents several challenges due to age-related physiologic changes, numerous comorbidities, use of multiple medications to include prescription, over the counter and
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herbal supplements, and multiple prescribing providers (Boparai & Korc-Grodzicki,
2011). Medications can play an essential role in maintaining the health of older adults
who frequently experience the burden of multiple chronic diseases with acute episodes.
The burden of multiple chronic diseases often requires taking multiple
medications concurrently, leading to an increase risk of an adverse drug event
(LeCouteur, Ford, & McLachlan, 2010). This has been defined as "an injury resulting
from the use of a drug" (Gurwitz et al., 2003, p.1109). In a study by Laroche et al. (2007)
the risk of adverse drug events were shown to increase 3.4 fold when older adults took 46 medications, 4.6 fold when using 7-9 medications, and 5.9 fold when 10 or more
medications were used. Delafuente (2003) reported an increase risk in the potential for
drug to drug interactions as the number of prescribed medications increased, showing a
probability of drug interactions rising to 50% with five drugs and as high as 100% with
eight drugs.
Drug interactions become a higher risk when multiple medications are required to
manage clinically complex individuals (Boyd, et al., 2005). As a result older adults are
frequently at risk for medication- related issues (Foust, Naylor, Boling & Cappuzzo,
2005) with all medication having the potential to harm as well as benefit (Tinetti,
Bogardus, & Agostini, 2004). And side effects, as a result of multiple medications, are
often mistaken as a new onset of illness and treated with a new medication or simply
accepted as a normal part of aging (Shrank, Polinski, & Avorn, 2007).
Therapeutic Drug Class
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Increased risk for side effects can occur in older adults as a result of the
significant differences in the way they metabolize medications (Hoskins, 2011).
Physiological changes occur with advanced age to include decrease in renal function,
decreased liver metabolism and alterations in the distribution of body water and fat that
all impact on drug metabolism (Huisman-Baron et al., 2011). Slabaugh et al. (2010)
reported older adults frequently used cardiovascular agents, antithrombotic agents and
gastrointestinal agents. However there is a lack of clarity of how medication-related
issues (therapeutic class of drug) relate to health-related quality in older adults (Classen,
Mkanta, Walsh, & Mann, 2005). The Beers Criteria developed explicit criteria to
identify potentially inappropriate medication (PIM) use by older adults (Beers, 1991).
The Beers Criteria published as original research in 1991, and revised in 2002 and
2012, identified a number of drugs and drug classes that were potentially inappropriate
for the elderly. These drugs were found to have a risk for adverse drug events (ADE) that
outweighed the potential for a therapeutic gain (American Geriatric Society, 2012a;
Beers,1997; Beers, Ouslander, Rollingher, Ruben, Brooks, & Beck,1991; Swagerty &
Brickley, 2005). The intention of the Beers Criteria was to reduce the use of potentially
inappropriate medications (PIMs) in older adults and improve prescribing decisions by
clinicians to reduce poor outcomes such as avoidable hospitalizations.
Budnitz et al. (2011) examined emergency hospitalizations in adults 65 years and
older and found that four medication classes either alone or in combination were
associated in 67% (95% CI, 60.0 to 74.1) of hospitalizations: warfarin (33.3%), insulins
(13.9%), oral anti-platelet agents (13.3%), and oral hypoglycemic agents (10.7%).
Almost 50% of hospitalizations for adverse drug events (ADEs) involved adults 80 years
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and older. Likewise, Boparai (2011) found the most common drug classes implicated in
ADEs in older adults included cardiovascular drugs, antibiotics, diuretics, steroids, anticholinergics, benzodiazepines and non-steriodal anti-inflammatory drugs.
Hospitalizations for ADEs are predicted to increase as adults live longer, experience
increased numbers of chronic conditions and consume more medications (Budnitz,
Lovegrove, Shehab, & Richards, 2011).
Similarly, Classen et al. (2005) compared medication drug classes and
inappropriately prescribed medications to functional status and quality of life in frail
home-based adults 65 years and older (n=1099) taking an average number of medications
of 5.4 (SD ± 3.7). Cardiovascular medications were the most frequently (72%) used
followed by gastrointestinal (41.3%), anti-inflammatory (41%) with cancer drugs having
the lowest frequency (1.7%). Cardiovascular drugs were shown to have a positive
association with motor performance (p=0.00) and cognition (p= 0.00). These findings
suggest that increased age, increased number of chronic conditions and decreased healthrelated quality of life are associated with greater number of medications.
The literature demonstrates that while there have been efforts to improve the
quality of medication use in older adults targeted towards specific issues (avoidance of
inappropriate drugs, drug classes and doses) have been important, they fail to include a
more patient-centric focus related to health-related quality of life.
Medication regimen complexity
Several studies have found complexity of a medication regimen is a significant
driver of poor medication adherence (Choudhry et al., 2011; Mansur, Weiss, &
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Beloosesky, 2012; Witticke, Seidling, Lohmann, Send, & Haefeli, 2013). Complex
medication regimens are more likely to be error prone which may impact patient safety
and quality of life (Paquin et al., 2013). In many situations the ability for an older adult
to remain independent at home hinges on their capacity to manage a complex medication
regimen, with non-adherence to regimens being a chief driver for nursing home
placement (Marek & Antle, 2008). Medication regimen characteristics such as the
number of medications, dosage frequency, drug route and administration directions
contribute to medication complexity resulting in lower adherence and increased risk for
adverse drug events (Corsonello et al., 2009; Elliot, O'Callaghan, Paul, & George, 2013;
Ingersoll & Cohen, 2008).
Clinical awareness regarding medication complexity can help identify patients at
higher risk for adverse outcomes. George et al. (2004) developed a 65 item medication
regimen complexity index tool as a way to quantify several components of medication
regimen complexity. Weights were assigned to dosage forms, frequency of doses, and
additional directions. The tool was validated by an expert panel that subjectively ranked
six regimens to confirm the tool's criterion-related validity demonstrating strong
agreement (Kendall's W = .8, p = 0.001). The value of the MRCI tool has gained recent
interest as evidenced by the translation of the tool to other languages (Stange et al.,
2012), additional studies further validating the tool (Mansur, Weiss, & Beloosesky, 2012;
Paquin et al., 2013) and other studies that have explored integrating the MRCI as part of
clinical decision making ( Elliot, 2012; Elliot et al., 2013; Libby et al., 2013; McDonald
et al., 2012; Rettig, Wood, & Hirsch, 2013).
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McDonald et al. (2012) further applied the MRCI by adapting it for use in
electronic health records (EHR) in a home-care setting. An automated process was
developed to measure medication regimen complexity in a large population of post-acute
discharged patients. The original paper-based MRCI (George et al., 2004) was adapted
using an electronic algorithm that automatically calculates the MRCI score for
medications entered into the EHR by a home care nurse. The number of total
medications was highly associated with the total MRCI score and the greatest contributor
to that score was dosing frequency (McDonald et al., 2012). This study provided the first
comprehensive picture of medication regimen complexity in a large cohort of post-acute,
community-dwelling patients characterized by multiple comorbidities and clinical
complexity. The use of an automated MRCI tool may assist clinicians to identify patients
with higher complexity with potential to improve medication management and overall
outcomes for patients.
Cardone et al. (2011) examined medication regimen complexity and healthrelated quality of life in end-stage kidney disease patients (n=35) recently started on
nocturnal home hemo-dialysis (NHHD) over a 24 month period. The SF-36 was used to
measure health-related quality of life and the Medication Regimen Complexity Index
(MRCI) was used to quantify regimen complexities. The MRCI scores increased
significantly when patients were started on NHHD with a baseline mean score of 22.4
(SD±10.2) and increased to a mean score of 28.3 (SD±11.6) at 24 months (p<0.05). The
researchers concluded that increases in the MRCI scores were most likely due to
dialysate requirements once NHHD was begun. SF-36 scores improved significantly
(p<0.05) from baseline through 24 months but MRCI scores were not significantly

MEDICATION COMPLEXITY AND HRQOL

28

related to the SF-36 score. Future studies are indicated to further explore the influence of
different measures of medication regimen complexity and clinical outcomes such as
health-related quality of life.
Wolf et al. (2011) explored whether patients inappropriately took multiple
medications more frequently than prescribed due the regimen complexity. They assessed
the accuracy and variability of how patients implemented a typical seven-drug regimen.
The findings indicated that many patients took medications more frequently than
indicated and those with inadequate literacy skills were a greatest risk for incorrect
dosing. Furthermore, an increase in medication regimen complexity can at a minimum
mean taking medication too often each day, causing adverse effects on overall health and
intrusion in patients’ lives.
Health-related quality of life and medication use
There is a need to better understand the potential intrusion that medication
regimen complexity may play in an older adult's life. Ebrahim (1995) stated generic
health-related quality of life measurements have a role in the evaluation of medication
therapy where unforeseen adverse effects of therapy might otherwise go unnoticed.
Youssef & Wong (2002) suggest there may be value to better understand the subjective
feelings of patients along with clinical assessment of health care interventions that
include medication regimens. This should also be evaluated according to its effect on the
health and quality of life of the individual. Henderson (2006) found the number of
medications were associated with lower SF-36 Physical Component Scores (PCS) and the
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number of medications (β= -.91, p= 0.045) to be predictive of lower health-related
quality of life in older adults.
Holt et al. (2010) found that low health-related quality of life scores were
associated with lower levels of anti-hypertensive medication adherence in adults over the
age of 65 years old. Those with low physical and mental component summary scores on
the Short Form (SF) 36 tool were 1.33 (95% CI 1.01, 1.74) and 2.26 (95% CI 1.74, 2.97)
times more likely, respectively, to have lower medication adherence than those with
higher PCS and MCS scores.
Older adults have a greater likelihood to experience multiple health issues that
will require the use of multiple medications, resulting in a potential decline in healthrelated quality of life (Cleary & Howell, 2007). Community-based older adults reported
an increase use of all medications with advancing age with the highest occurrence of drug
use in females 65 years and older with 12% taking 10 or more medications (Kaufman,
Kelly, Rosenberg, Anderson & Mitchell, 2002). Cleary & Howell (2007) examined
health-related quality of life and prescription medication use in a study sample of adults
aged 65 years and older (n=46) living in a rural region of the United States. The Short
Form-36 version 2 (SF-36 v2) was used to measure health-related quality of life.
Differences between subjects SF-36v2 physical component summary (PCS) and mental
component (MCS) scores were compared based on gender and age and showed the mean
PCS score for women was slightly better than men with a trend toward significance (p=
0.06). This study supported the perception that health-related quality of life declines with
age but did not find an association with prescription medication use. Of note, the average
number of medication used (3.3) of the study subjects was lower than the national
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average for older adults (4-5). The implications of these findings as they relate to the
current study are: 1) the mean number of medications in the current study will be
expected to be higher; 2) the subjects are from an urban area; 3) there is greater racial and
ethnic diversity; and 4) the sample size will be larger (n=123).
Likewise, Henderson et al. (2006) examined the association of health-related
quality of life and polypharmacy to determine the influence of demographic and clinical
characteristics on this relationship among a group of older American Indians. An in-home
interview and survey were conducted on a convenience sample (n = 63) of communitydwelling American Indians. The independent variables included total number of all
prescription and nonprescription medications, age, education, annual income, health
insurance, perceived health and medical history. The Medical Outcomes Short Form-36
(SF-36) was used to measure health-related quality of life. Increased use of medications
were significantly associated with poorer self-reported health with the mean PCS score of
36.5, (r=.30, p=.02). The study will build upon the literature in the following ways: (a)
the subjects reside in an urban area; (b) larger sample size, and 3) majority are Hispanic
older adults.
While there have been efforts to improve the quality of medication use in older
adults targeted towards specific issues to include avoidance of inappropriate drugs,
specific drug classes and doses (Beers, 1991; Budnitz et al., 2011) have been important,
they fail to include a more patient-centric focus related to health-related quality of life.
Identifying outcome measures specific to health-related quality of life continues to pose
challenges for nursing. Traditional measures, for example morbidity and mortality, do not
provide adequate information concerning health-related quality of life. Yet clinicians may
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remain unconvinced concerning the clinical significance of health-related quality of life,
possibly because there is a paucity of research linking health-related quality of life to
nursing-sensitive indicators (Sousa & Williamson, 2003).
Summary
While the literature pertaining to health-related quality of life has emerged as a
significant clinical indicator for older adults with chronic health problems, the evidence
linking the use of multiple medications, therapeutic drug class, and medication regimen
complexity, and health-related quality of life in older adults is lacking, and in particular
in ethnically diverse older adults. Although the use of multiple medications has been
widely explored in the literature, this literature review highlights the gaps regarding
whether specific medication-related factors (number of active medications, number of
therapeutic drug classes, medication regimen complexity) are related to health-related
quality of life in older adults. The findings from this study explored whether key
medication-related factors had a significant impact on health-related quality of life.
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Chapter III
The Method
The primary goal of this study was to examine the relationships of medicationrelated factors (the number of active medications, the number of therapeutic drug classes,
and medication regimen complexity) with health-related quality of life in older adults
receiving home and community-based services. The methodology used to test the
research questions and hypotheses is presented in this chapter which is organized into six
sections: a) overview of the primary study, b) study design, c) study sample and setting,
d) data collection, e) instrumentation, and f) data analysis.
Primary Study Overview
The data for this secondary analysis came from the baseline interviews and
electronic health record abstractions of a large multi-site, longitudinal study investigating
health-related quality of life in older adults recently transitioned to long term support
services (LTSS). The primary study, Health Related Quality of Life: Elders in Long Term
Care (R01-AG025524, PI, M. Naylor) was designed to examine the natural history of
changes in health-related quality of life among older adults in three distinct settings to
include nursing homes (NH), assisted living facilities (ALF) and home and communitybased services (H&CBS) and compare patterns of change in each of the multiple
domains of health-related quality of life across long-term care settings by examining
patterns among matched samples of older adults who remained in their setting for at least
one year. Eligibility criteria included adults age 60 years and older who were newly
admitted (within 60 days) to one of the LTSS options; able to communicate verbally in
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English or Spanish. Exclusion criteria included severe cognitive impairment (MMSE
score of less than 12 at baseline), active psychiatric disorders, terminal illness, or
admission to a LTC option for post-acute services with an expected plan for discharge
from the LTC site. The primary study site locations took place at two visiting nurse
agencies (H&CBS) providing in-home LTSS (one was located in New York, NY); nine
NHs; nine ALFs and two Program for All Inclusive Care of Elderly (PACE) programs.
With the exception of the New York-based home and community-based agency, all study
sites were located in the Philadelphia area. Subject recruitment for the primary study was
conducted at each study site based on eligibility criteria. Designated site staff approached
eligible potential subjects to describe the study. The names of subjects who were
interested in learning more were then provided to study project staff who explained the
study, administered the MMSE and sought informed consent. Those subjects with
MMSE scores of 12 or below were excluded and subjects with a score between13-22
required additional consent from their legally authorized representative. The primary
study commenced in 2007 (Hirschman, Abbott, Hanlon, Bettger, & Naylor. 2012) and
data collection was completed in 2012.
Design
This study was a secondary data analysis using baseline data collected by the
primary study (R01AG025524-01A2, Principal Investigator, M. Naylor).
Study Sample and Setting
As part of the multi-site primary study, Visiting Nurse Service of New York
(VNSNY) CHOICE Health Plan was asked to recruit eligible older adults recently
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admitted to their program to receive community-based LTSS. A review of the VNSNY
CHOICE member census identified the Washington Heights and Inwood neighborhoods
as having potentially eligible research subjects. Washington Heights and Inwood have a
higher proportion (71%) of Hispanic residents than other areas in Manhattan (27%) and
NYC overall (27%) (U.S Census, 2011). According to Bergad (2008), beginning in the
1980s, the upper Manhattan neighborhoods of Washington Heights and Inwood have
become home to a large Hispanic population, making up 73% of the population by 2005
with Dominicans representing the most prominent ethnic group.
The sample for this study consisted of community-dwelling older adults (n =123)
who were enrolled during 2007 and 2008 in the primary study (N = 470) previously
described (R01-AG025524, PI, M. Naylor). Inclusion criteria for this study included
individuals who were: 1) enrolled in the primary study, 2) aged 60 years and older, and 3)
were recent recipients (within 60 days) of home and community-based services in New
York City. Exclusion criteria for this study excluded any subject who did not reside in the
community at time of enrollment. The initial baseline sample (n = 124) included all
recruited subjects from the VNSNY site. One subject lived in an assisted living facility
(ALF) and was therefore excluded.
Human Subjects Protection
The policies and procedures of the Graduate Center of City University of New
York and the Visiting Nurse Service of New York (which participated in the primary
study and where this researcher was employed) were followed to seek and receive
approval from their internal review boards (IRBs). The primary study had already been
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approved by the Visiting Nurse Service of New York and the University of Pennsylvania
IRBs. Certain medication-related factors were not collected as part of the baseline data by
the primary study researchers. Therefore, additional medication-related factors including
dosage form/route (e.g. tablet, injection) and additional directions (take with food, crush
pill) required access to the subjects’ electronic health record for the additional data.
VNSNY IRB approval was sought and obtained to re-identify subjects to facilitate access
of the electronic health records to attain medication information. IRB approval was also
received from Hunter College, CUNY in accordance with Graduate Center policies.
Data Collection
Data for this secondary analysis were collected by the primary study as part of
the baseline face to face interviews conducted at the time of enrollment and by retrieving
data from electronic health records. Following IRB approval, the VNSNY baseline data
set was re-identified and the additional medication-related data were obtained from the
subject’s electronic health record (EHR) by this researcher. Following retrieval of all
medication data from the subject’s EHR data were de-identified and recorded on
Microsoft excel spreadsheets using a password-protected computer with access limited to
this researcher only. To ensure all study data were examined at the same time point, the
date of enrollment (see Appendix B) was used to retrieve the additional medicationrelated data from the subject’s EHR.
Instruments and Data Collection Procedures
Demographic data measurement
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Baseline demographic data included age, gender, education, race, ethnicity,
marital status and cognitive status. This data was obtained during the initial in-home
interviews. These data were collected by the primary study on the demographic
questionnaire (see Appendix G) as part of the Health Related Quality of Life Baseline
Subject Interview developed and used in the primary study.
Baseline HRQoL Chart Abstract Tool with Medication Data
The baseline HRQoL chart abstract tool (see Appendix C) collected the date of
enrollment in the primary study. The tool was designed by the primary study to abstract
data from the study subject's electronic health record to include their active medication
list (see Appendix A). The baseline medication information initially collected by the
primary study at baseline only included the name, dosage and frequency for each
medication. The dosage form (tablet, injection) and additional directions (take with food,
take at bedtime) were not included and were required to measure medication regimen
complexity scores and were collected by this researcher.
Cognitive Status
The Mini Mental State Exam (MMSE) was used in the primary study to measure
cognitive status. The MMSE is a widely used global cognitive assessment tool that
measures orientation to time and place, recalls ability, short-term memory and arithmetic
ability in older adults (Folstein, Folstein, & McHugh, 1975). It consists of 20 questions,
divided into two sections (see Appendix B). The first section requires verbal responses to
orientation, memory, and attention questions, and the second section requires reading and
writing and covers the ability to name, follow verbal and written commands, write a
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sentence, and copy a polygon. The MMSE total score ranges from 0 to 30 and reflects the
number of correct responses. Older adults scoring 24 or higher are considered to be
cognitively intact, those with scores of 23-20 are mildly impaired and older adults with
scores of 19-12 are moderately impaired (Pangman, Sloan, & Guse, 2000). For the
purposes of regression analysis this variable was recoded to dichotomize cognitive status
into cognitively intact (MMSE score ≥ 24) and cognitively impaired (MMSE ≤ 23).
Medical Outcomes Study Short Form (SF-12v2)
Health-related quality of life was measured using the Medical Outcome Study
(MOS) Short Form (SF-12v2) which is a multi-purpose generic measurement of healthstatus (Ware, Kosinki, & Keller, 1996). The MOS SF-12v2 (see Appendix D) is a
psychometrically rigorous instrument frequently used by clinicians and researchers to
measure and assess health- related quality of life in a variety of patient populations
(Brazier & Roberts, 2004; Borglin et al., 2004; Gandhi et al., 2001; Larson et al., 2008;
Montazeri et al., 2011; Resnick & Nahm, 2001; Sousa & Williamson, 2003;). The SF12v2 contains 12 items, with a range of 3 to 5 response levels that measure eight aspects of
general health to include physical functioning, role limitations due to physical health
issues, bodily pain, general health, vitality, social functioning, role limitations due to
emotional problems, and mental health (Ware et al., 1996). The instrument uses a Likert
scale of 1 to 3 for physical function items; 1 to 5 for bodily pain, social function and
general health perception items; 1 to 5 for vitality and mental health; and a dichotomous
scale (yes/no) for the presence of role function items (Ware, Kosinski, & Keller, 1996).
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The purpose of the MOS SF-12v2 in this study was to measure both physical and
mental health-related quality of life using the physical component score (PCS-12) and
mental component score (MCS-12) respectively. The sample (N=123) mean (M) and
range results are noted for each item for both component scores (see Table 4.6). Higher
scores indicate better self-perceptions of health.
PCS-12 and MCS-12 scores can range between 0 to 100, with 0 indicating the
lowest level of health and 100 indicating the highest level of health (Ware, Kosinski, &
Keller, 1996). Scoring of the SF-12 v2 PCS-12 and MCS-12 were created using normbased methods that standardized the scores to a mean of 50 and a standard deviation of
10. Norm-based scoring facilitates comparison of sample scores against the general
population (Resnick & Nahm, 2001). The test-retest reliability for the PCS-12 was .89
and the reliability coefficient of .76 was observed for MCS-12 in the general U.S.
population (Ware et al., 1996, p.29).
Based on reliability estimates, the MOS SF-12v2 performed adequately in this
study sample (N =123). Internal consistency for the SF 12 v.2 instrument for this sample
was determined using the Cronbach's alpha coefficient. The results for this study (N
=123) showed Cronbach's alpha coefficient for the physical component score approached
0.70 (α for PCS-12 was .662) and the mental component score exceeded 0.70 (α for
MCS-12 was .765).
Active Medication Data Collection Procedure
Active medications, created as a continuous variable, were defined as the number
of medications a subject was taking and included both prescription and over the counter
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medications. Data for active medications comprised a total of 1138 medications for the
sample (N =123) with subjects taking an average of 9.3 medications (range 2-19) (see
Table 4.2). Medication data was obtained from the medication list documented by a
registered nurse in subject’s electronic health record (EHR). Medication data included the
medication name, form or route (e.g. tablet, injection), frequency (e.g. once a day) and
additional directions (e.g. take with food, crush tablet) and were routinely entered and
documented in the subject’s EHR by home care nurses using tablet computers as part of
usual care (personal communication, M. McDonald November 11, 2013). In addition to
prescription medications, over the counter medications were included in the EHR
medication list as part of usual practice as they often play a vital role in a patient’s
treatment plan and have potential to interact with prescription medications (McDonald et
al., 2012). All medication data retrieved from the subject’s EHR were de-identified and
recorded on Microsoft excel spreadsheets stored in a password-protected computer with
access limited to this researcher only.
Therapeutic Drug Class Measurement Tool
To enhance the precision of data about medication-related factors, this researcher
developed a therapeutic drug class tool (see Appendix F) to measure the number of
individual therapeutic drug classes represented in the subject’s medication regimen. Each
medication that shared the same therapeutic class was matched according to one of the 12
pre-determined therapeutic drug classifications in the established drug reference, Drug
Facts and Comparisons 2013. A 13th drug classification labeled "Other" was created to
capture any medications that did not fit into any of the established drug classifications
(e.g. Fish oil, Glucosamine). Each medication was assigned a therapeutic drug class (e.g.
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cardiovascular, central nervous system, respiratory). Unique therapeutic drug classes
were only counted once for each medication regimen. For example, a study subject taking
two cardio-vascular medications and two gastrointestinal medications would have a total
of two therapeutic drug classes (cardiovascular, gastrointestinal) counted in their
regimen. The average number of therapeutic drug classes represented in the study sample
was 4.89 with a range of 2-8 and was analyzed as a continuous variable (see Table 4.3).
Medication Regimen Complexity Index
Medication regimen complexity was measured using the Medication Regimen
Complexity Index (MRCI) (George et al., 2004). The MRCI is a valid and reliable
instrument with strong inter-rater and test-retest reliabilities ≥0.9 (Elliot et al., 2013;
George at el., 2004) The MRCI is a 65-item tool designed to quantify prescription
medication in three components of medication regimen complexity. For the purpose of
this study, over the counter medications were also included in addition to prescription
medications. MRCI component "A" measures dosage form/route (e.g. tablets, eye drops,
injections). Each dosage form/route is counted only once within a regimen. For example,
if a patient's regimen consists of four tablets that are taken orally, their MRCI component
“A” sub-score would be one. The MRCI component "B" measures dosing frequency (e.g.
once a day, every 12 hours, alternate days) for each medication. A weight is given to each
medication frequency, with higher weights assigned to greater frequencies. For example,
if a patient is taking six medications with a frequency of once a day for each medication,
the MRCI component B subscore would be six. The third MRCI component “C”
measures additional directions (e.g. crush pill, take with food, taper dose). A weight is
given for each instruction per medication. For example, if a patient is on a single
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medication that needs to be crushed and taken with meals, the component C score for that
medication is two. The Medication Regimen Complexity Index is a summary score of all
three components. There is no limitation to the number of medications or special
directions that may be prescribed for a patient, and as a result the MRCI is an open index
without upper limitations for ranging scores with higher scores indicating greater
complexity (George et al., 2004). The range of total MRCI scores for this study sample
ranged from 3 to 69, with a mean total score of 20.6 and was analyzed as a continuous
variable (see Table 4.2).
The paper-based MRCI tool was adapted for electronic use in a study conducted
in a large home and community-based organization (McDonald et al., 2012), the setting
for the study sample used in this secondary analysis (and where this researcher was
employed). McDonald et al. (2012) analyzed medication regimen complexity from
electronic health records (EHR) of a large sample (N=89,645) of elderly home-care
patients to develop and test the translation of the original MRCI components into an
automated algorithm tool within the EHR. Scores for MRCI components A and B were
calculated by directly mapping to electronic fields that contained this information.
Certain regimens were abstracted and manually scored to ensure the programming was
working correctly.
Once all data were available to compute the MRCI score for each study subject,
this researcher completed a paper-based MRCI tool and calculated component and total
scores for each subject's medication regimen. The MRCI results were then analyzed
using SPSS Version 21. Inter-rater reliability between the paper-based MRCI scores
computed by this researcher and MRCI scores computed using the electronic algorithm
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(EA) method previously described was tested. After receiving IRB approval, a researcher
familiar with the development of the electronic MRCI algorithm scored 100% of the
study sample (T. Peng, personal communication, July 13, 2013). Strong, positive
statistically significant correlations were found for the total number of medications (r =
.995, p ≤ .01) (see Table 3.1) and for all three MRCI components (dose forms, dosing
frequencies, additional directions), demonstrating high degree of agreement between
paper-based and electronic scores. The electronic algorithm (EA) MRCI scores were
strongly and positively correlated with the researcher’s paper-based (PB) MRCI scores,
specifically dosage form (MRCI A) (r = .954, p ≤ .01), dosing frequency (MRCI B) (r =
.991, p ≤ .01), additional directions (MRCI C) (r = .895, p ≤ .01) and MRCI total scores
(r = .984, p ≤ .01).
Table 3.1
Inter-rater Reliability for Medication Regimen Complexity Index (MRCI) tool: VNSNY
Electronic Algorithm (EA) and Paper-based (PB) MRCI
Total Active
Medications
(EA)

Variable

Total
Medications

Active

MRCI A (PB)
MRCI B (PB)
MRCI C (PB)
MRCI Total (PB)
Note. **p ≤..001

MRCI A
(EA)

MRCI B
(EA)

MRCI C
(EA)

MRCI
Total (EA)

.995**

.954**
.991**
.895**
.984**
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Data Analysis
This study utilized a quantitative methodology for data collection and analysis.
Prior to analyses, data were examined for accuracy and missing items. It was determined
the health-related quality of life instrument, MOS SF-12 v2, had 4.8% (n=6) missing
data. The missing data is just below the 5% missing data criterion recommended by
Tabachnick and Fidell (2007). The total count of active medications, Therapeutic Drug
Class and MRCI tool instruments had no missing data. To address the missing data, cases
with missing data were excluded pair-wise which excludes the cases only if they are
missing data required for the specific analysis (Tabachnick & Fidell, 2007).
The study covariates age, gender, race, ethnicity, education, marital status, and
cognitive status were originally collected by the primary study. For regression analysis,
certain variables were recoded as new dummy or dichotomized variables. Age was kept
as a continuous variable. Gender recoded as (0= female/ 1= male). Cognitive status was
dichotomized (no impairment = 0 [MMSE >12 <23] / impaired =1 [MMSE ≥23]).
Marital status was dichotomized (married = 0/ not married =1). Ethnicity was
dichotomized and recoded (Hispanic = 1/ not Hispanic =0).
Normality of variables was assessed using statistical and graphical methods to
include histograms to identify outliers and the shape of distributions were examined for
evidence of normal distribution. Descriptive statistics to include measures of central
tendency were computed for study variables and for appropriate demographic data. The
researcher examined the relationship between the number of active medications and the
dependent variable (physical health-related quality of life) using Pearson’s product-
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moment correlation. Partial correlations were computed to control co-variants (age,
gender, education, race, ethnicity, marital status, and cognitive status). Full model
multiple regressions were conducted for all covariates and physical and mental healthrelated quality of life. The 0.5 alpha level was the criteria used for statistical significance
in all analyses. Data were analyzed using the Statistical Packages for the Social Sciences
(SPSS) Version 21.0 for Windows program to run statistical tests.
Linear regression analyses was the analytical approach conducted to test all six
research hypotheses to determine: (a) if the number of active medications predicted
physical and mental health-related quality of life, (b) if the number of therapeutic drug
classes predicted physical and mental health-related quality of life, and finally (c) if
medication regimen complexity predicted physical and mental health-related quality of
life.
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Chapter IV
The Results

This chapter presents the results of the statistical data analysis. The statistical
findings of study are presented in three main sections: (a) descriptive statistics of sample
characteristics and study variables, (b) main analysis to include linear regression models,
for the six study hypotheses and (c) ancillary analysis. Presentation of the findings was
summarized in narrative format and depicted in table format.
Descriptive Statistics
Sample Characteristics
The study sample was comprised of 123 older adults who recently began
receiving home and community-based services provided by a home and communitybased agency. Overall subjects were 79 years old on average, the majority were female
(75%), and Hispanic (68%). Fifty-nine percent only had an 8th grade education (see Table
4.1). The majority of subjects (84%) had a mean MMSE score of 24.7 and almost half
(42%) were widowed. Over one third (35%) of the sample were Black or African
American. Of note, 37% (n =46) chose the "Other" category for race (see Appendix G).
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Table 4.1
Sample characteristics of older adults receiving H&CBS in Washington Heights and
Inwood, NY, during 2007-2008 (N =123)
Demographic
Characteristics
Age
≤ 75 years
76 - 83 years
≥ 84 years

%

n

Mean (SD)

Range (Min - Max)

123
44
38
41

79 yrs (7.7)

34 (63-97)

36
31
33

Gender
Female
Male

75
25

92
31

Education
≤ 8th grade
9 - 12 years
> 12 years

8 yrs (4.5)

21 (0 - 21)

59
28
13

72
35
16

28
35
1.6
37

35
41
2
46

68

84

24
42
10
24

29
52
12
29

Race
White
Black or AA
Native Hawaiian Pacific
Other
Ethnicity
Hispanic
Marital Status
Married
Widowed
Single
Divorced/Separated

Cognitive Status
122
24.7 (2.94)
16 (14-30)
Impaired (MMSE >12
16
20
<23)
Not Impaired (MMSE
84
102
≥23)
Note. H&CBS = Home and Community-Based Services. MMSE = Mini Mental State
Exam. AA = African American
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Medication-related Factors
Active medications. The average total number of active medications was 9.3 (SD
3.6) with a range of 2-19 (see Table 4.2).
Table 4.2
Total Active Medications and Medication Regimen Complexity Characteristics of older
adults receiving H&CBS in Washington Heights and Inwood, NY, during 2007-2008
(N =123)
Medication Variables

Mean (SD)

Range

Total Number of Active
Medications* (unduplicated
count)

9.3 (3.6)

17 (2 - 19)

MRCI A (dosage forms)

4.8 (4.3)

21 (1 - 22)

MRCI B (frequency)

13.7 (6.7)

26 (2 - 38)

MRCI C (directions)

2.1 (2.2)

12 (0 - 12)

20.6 (11.6)

66 (3 - 69)

MRCI Total Score

Note. * Includes prescription and over the counter medications. MRCI = Medication
Regimen Complexity Index

Medication regimen complexity. MRCI total scores ranged from 3 to 69 (see
Table 4.2) with a mean average of 20.6 (SD 11.6). The greatest contributor to the MRCI
total score was dosing frequency (MRCI B) with a mean score of 13.7 (SD 6.7) with a
range from 2 to 38, thus representing multiple medications and multiple dosing patterns.
There was a strong correlation between the number of medications and the MRCI total
score (r=.839, p≤.001) (see Table 4.7).
There was wide variance of MRCI total scores found within regimens containing
the same number of medications as noted in the two sample medication regimens (see
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Tables 6 and 7). To illustrate this point, the MRCI total scores for 2 study subjects taking
9 medications a day were compared to demonstrate the wide variance of medication
regimen complexity. The MRCI total score computed in Regimen “A” was 25 and the
MRCI score computed in Regimen “B” was 11 (see Figure 4.1).

Figure 4.1. Scatterplot of medication regimen complexity (MRCI) and total
active medications with example regimens for 2 subjects taking 9 medications.

The first medication regimen example (see Table 4.3) was more complex with a
MRCI total score of 25, which is approximately 25% higher than study sample average
(20.6). The higher complexity was attributable to 1) multiple routes/forms (tablet and two
forms of inhaled medications), 2) frequencies ranging from once daily up to every four
hours as needed and 3) two additional directions (taking medication at a specific time
(bedtime) and the using of multiple units (2 puffs) at one time).
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Table 4.3
Medication Regimen Example A: Older adult receiving H&CBS in Washington Heights
and Inwood, NY, during 2007-2008 (n=1)
Medication Regimen A: 9 medications with MRCI total score = 25
Medication
Form / Route
Frequency (MRCI B) Directions (MRCI C)
(MRCI A)
Singular
Tablet / Oral
Once a day
Take a bedtime
Motrin
Tablet / Oral
Every 4 hours prn
HTCZ
Tablet / Oral
Once a day
Micardis
Tablet / Oral
Once a day
Amlodipine
Tablet / Oral
Once a day
Calcium
Tablet / Oral
Once a day
Advair Diskus
Inhalation /
Twice a day
Multiple units (2
Aerolizer
puffs)
Spiriva
Inhalation /
Once a day
Accuhaler
Ferrous Sulfate
Tablet/ Oral
Every 8 hours
Note. HCTZ = Hydrochlorothiazide. MRCI = Medication Regimen Complexity Index.
PRN = take as needed
The medication regimen in the second example (see Table 4.4) was less complex
than was typical for patients taking nine medications. The MRCI score of 11 was
approximately 49% lower than study sample average (20.6). The lower complexity in this
example was attributable to using only one route/form (oral/tablet/capsule) with a once a
day frequency for eight out of nine medications with no additional directions indicated.
Table 4.4
Medication Regimen Example B: Older adult receiving H&CBS in Washington Heights
and Inwood, NY, during 2007-2008 (n=1)
Medication Regimen B: 9 medications with MRCI total score = 11
Medication
Form/Route (MRCI A) Frequency (MRCI B) Directions (MRCI C)
Avandia
Tablet / Oral
Once a day
Vitamin C
Tablet / Oral
Once a day
Omega 3
Capsule / Oral
Once a day
Lipitor
Tablet / Oral
Once a day
Glimepiride
Tablet / Oral
Twice a day
Prevacid
Capsule / Oral
Once a day
Aspirin
Tablet / Oral
Once a day
Allopurinol
Tablet / Oral
Once a day
Lisinopril
Tablet / Oral
Once a day
-
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Therapeutic drug class. On average, the medication regimens of the subjects
were comprised of five unique therapeutic drug classes with a range from two to eight
classes. The five most prevalent therapeutic drug classes (see Table 4.5) were
cardiovascular agents (97%), central nervous system agents (94%), nutrients and
nutritional agents (63%), gastrointestinal agents (60%), and endocrine and metabolic
agents (59%). Systemic anti-infective agents (6%) and biologic and immunologic agents
(4%) had the lowest frequency of use.
Table 4.5
Characteristics of Therapeutic Drug Class (TDC) of older adults receiving H&CBS in
Washington Heights and Inwood, NY, during 2007-2008 (N =123)
Therapeutic Drug Class

%

Unique TDC per regimen

N

Mean (SD)

Range

123

4.89 (1.5)

6 (2-8)

TDC Frequencies
Cardiovascular

97

119

Central Nervous System

94

116

Nutrients & Nutritional

63

78

Gastrointestinal

60

74

Endocrine & Metabolic

59

73

Respiratory

35

43

Hematological

20

25

Renal & Genitourinary

16

20

Ophthalmic & Otic

13

16

Dermatological

11

13

Other

8

10

Systemic Anti-infective

6

7

Biologic & Immunologic

4

5

Note. TDC = Therapeutic Drug Class
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Health related quality of life

Health-related quality of life was measured using the Medical Outcomes Study
Short Form (SF-12v2) (see Table 4.6). The SF-12v2 produces two component scores
(physical component score [PCS-12] and mental component score [MCS-12]) with higher
scores indicating better health-related quality of life (Ware et al., 2002). The results for
the six items in the PCS-12 were in the lower range, measuring physical functioning (M=
1.28) (range 1 -3), role limitations due to physical health problems to include limited stair
climbing (M = 1.28) (range 1-3), accomplishing less (M = 2.8) (range 1-5), limited work
or activities (M = 2.77) (range 1-5), bodily pain (M = 3.18) (range 1-5) and general health
(M =(range 1-5). Physical health-related quality of life for the study sample indicated
lower than average physical health ratings. The mean PCS-12 score of 31.2 (SD 7.66) for
the sample which is well below the average norm-based PCS-12 score of 50 (Resnick &
Nahm, 2001).
The results for the six items in the MCS-12 were higher range measuring vitality
(energy) (M = 2.58) (range 1-5), social functioning (M = 3.24) (range 1–5), role emotion
(accomplished less) (M =3.46) (range 1-5), role emotion (not careful) (M =3.76) (range
1-5), mental health (felt calm & peaceful) (M = 3.43) (range 1-5), mental health
(downhearted and depressed) (M = 3.24) (range 1-5). The average MCS-12 was higher
than the PCS-12 with a mean score of 47.3 (SD 10.5) which is closer to the norm-based
average of 50 (Resnick & Nahm, 2001). The study subjects on average had higher mental
component scores when compared to their physical component scores (PCS-12).
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Table 4.6
Characteristics of Health related Quality of Life of older adults receiving H&CBS in
Washington Heights and Inwood, NY, during 2007-2008 (N =117)
MOS SF-12v2

Mean (SD)

Range (Min-Max)

Physical HRQoL
(PCS-12)

31.2 (7.66)

37 (14-51)

Mental HRQoL
(MCS-12)

47.3 (10.5)

56 (14-70)

Note. MOS SF-12v2 = Medical Outcomes Study Short Form (SF-12 v2). PCS-12 =
Physical Component Score. MCS-12 = Mental Component Score.

Main Analysis
Main analysis examined the relationships between the dependent variables,
physical and mental health-related quality of life, and the independent variables: number
of active medications, number of therapeutic drug classes, and medication regimen
complexity. The correlation matrix for the study variable is reported on Table 10.
Cohen’s (1988) guidelines for evaluating correlational results for the behavioral sciences
were used to interpret the strength of the correlations. The study sample size (N = 123)
met the required number of minimum cases recommended when using multiple
regression. Preliminary analyses were conducted to determine there were no violation of
assumptions of normality, linearity, outliers, multicollinearity and homoscedasticity
(Tabachnick & Fidell, 2007). The Normal Probability Plots (P-P) suggested no deviation
from normality. The scatterplot of the standardized residuals supported homoscedasticity
and indicated no visible patterns or outliers. Collinearity diagnostics for the independent
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variable (VIF =1.0, Tolerance = 1.0) did not violate the assumption of multicollinearity.
The maximum value for Cook’s Distance was .28 suggesting no major issues of undue
influence on the results. Scores larger than 1.00 are most likely due to outliers
(Tabachnick & Fidell, 2007).
Table 4.7
Correlation Matrix of Associations Among Main Study Variables (N =123)
Variable

Physical
HRQoL
(PCS-12)
Mental
HRQoL
(MCS-12)

Physical
HRQoL
(PCS-12)

Mental
HRQoL
(MCS-12)

Total Active
Medications

Therapeutic
Drug Class

MRCI
Total Score

-.117

-.185*

-.046

-.081

-.101

-.157

-.076

.720**

.839**

Total Active
Medications
Therapeutic
Drug Class

.651**

Note.**p ≤.001, one tailed. *p ≤ .05. HRQoL = Health-related quality of life. PCS-12 =
Physical Component Score. MCS-12 = Mental Component Score. MRCI = Medication
Regimen Complexity Score.
Testing the Research Hypotheses
Research question 1. Is there an association between the number of active medications
and health-related quality of life in older adults receiving community-based LTSS before
and after controlling for age, gender, education, race, ethnicity, marital and cognitive
status?
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H1a: The number of active medications will be associated with physical healthrelated quality of life in of older adults receiving community-based LTSS.
A Pearson product-moment correlation was calculated to explore the relationship
between the number of active medications (M = 9.3) and physical health-related quality
of life (measured by PCS-12) (M = 31.2). Before controlling for age, gender, education,
race, ethnicity, marital and cognitive status, this analysis was found r = -.185, indicating a
small negative relationship between the total number of active medications and physical
health-related quality of life.
Partial correlation was used to explore if the relationship between physical healthrelated quality of life and the total number of active medications while controlling for
age, gender, education, race, ethnicity, marital and cognitive status. There was a small,
negative partial correlation between physical health-related quality of life and the total
number of active medications controlling for age, r = -.194, p <.05, education , r = -.185,
p <.05, race r = -.184, p <.05, ethnicity, r = -.185, p <.05, marital status, r = -.188, p
<..05, and cognitive status, r = -.193, p <.05. An inspection of the zero order correlation
(r = -.185) suggested that controlling for age, education, race, ethnicity, marital and
cognitive status had very little effect on the strength of the relationship between the two
variables. There was a small decrease in the strength of the correlation (from -.185 to .171) when controlling for gender, r = -.171, p =.06.
A simple linear regression was performed (see Table 4.8). It was found that the
total number of medications significantly predicted physical health-related quality of life
(β = -.185, p = .046). A multiple regression was than conducted adjusting for age, gender,
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education, race, ethnicity, marital status and cognitive status. After adjusting for the
covariates, the predictive power of total number of active medications on physical healthrelated quality of life was reduced (β = -.186, p = .062) (see Table 4.8). These results
indicated that for every unit increase in medication, physical health-related quality of life
decreases by .5, interpreted to mean that people taking more medications will have a
decrease in physical health-related quality of life.
H1b: The number of active medications will be associated with mental healthrelated quality of life in of older adults receiving community-based LTSS.
A Pearson product-moment correlation was calculated to explore the relationship
between the number of active medications (M = 9.3) and mental health-related quality of
life (MCS-12) (M = 47.3). This analysis found that there was a non-significant
correlation, r = -.101, p >.05, between the number of active medications and mental
health-related quality of life.
A simple linear regression was performed before adjusting for age, gender,
education, race, ethnicity, marital status and cognitive status (see Table 4.9). The total
number of active medications did not predict mental health-related quality of life (β = .101, p = .279). A multiple regression was then conducted adjusting for age, gender,
education, race, ethnicity, marital status and cognitive status. After adjusting for the
covariates, the total number of active medications did not predict mental health-related
quality of life (β = -.041, p = .676).
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Research Question 2
Research question 2. Is there an association between the number of therapeutic drug
class and health-related quality of life of older adults receiving community-based LTSS
before and after controlling for age, gender, education, race, ethnicity, marital and
cognitive status?
H2a: The number of therapeutic drug classes will be associated with
physical health-related quality of life in older adults receiving community-based LTSS.
A Pearson product-moment correlation was calculated to explore the relationship
between the number of therapeutic drug classes (M = 4.9) and physical health-related
quality of life (PCS-12) (M = 31.2). This analysis found that there was a non-significant
correlation, r = -.046, p >.05, between the number of therapeutic drug classes and
physical health-related quality of life.
A simple linear regression was performed before adjusting for age, gender,
education, race, ethnicity, marital status and cognitive status (see Table 4.8) The number
of therapeutic drug classes did not predict physical health-related quality of life (β = .046, p =.623). A multiple regression was then conducted adjusting for age, gender,
education, race, ethnicity, marital status and cognitive status. The results of the regression
indicated that the number of therapeutic drug classes did not predict physical healthrelated quality of life (β = -.044, p = .651) (see Table 4.8).
H2b: The number of therapeutic drug class will be associated with mental healthrelated quality of life in older adults receiving community-based LTSS.
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A Pearson product-moment correlation was calculated to explore the relationship
between the number of therapeutic drug class (M = 4.9) and mental health-related quality
of life (MCS-12) (M = 31.2). Before controlling for gender, age, education, marital status,
ethnicity, race, and cognitive function, this analysis found that there was a non-significant
correlation, r = -.091, p >.05, between the number of therapeutic drug classes and mental
health-related quality of life.
A simple linear regression was performed before adjusting for age, gender,
education, race, ethnicity, marital status and cognitive status (see Table 4.9). The total
number of therapeutic drug classes did not predict mental health-related quality of life (β
= -.157, p = .091). A multiple regression was then conducted adjusting for age, gender,
education, race, ethnicity, marital status and cognitive status. After adjusting for the
covariates, the number of therapeutic drug classes did not predict mental health-related
quality of life (β = -.114, p = .230) (see Table 4.9).
Research Question 3
Research question 3. Is there an association between medication regimen
complexity and health-related quality of life in older adults receiving community-based
LTSS before and after controlling for gender, age, number of years of education, marital
status, ethnicity, race, and cognitive status?
H3a: Medication regimen complexity will be associated with physical healthrelated quality of life in older adults receiving community-based LTSS.
A Pearson product-moment correlation was calculated to explore the relationship
between medication regimen complexity (M = 20.6) and physical health-related quality of
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life (PCS-12) (M = 31.2). This analysis found that there was a non-significant correlation,
r = -.081, p >.05, between the medication regimen complexity and physical health-related
quality of life.
A simple linear regression was performed before adjusting for age, gender,
education, race, ethnicity, marital status and cognitive status (see Table 4.8) Medication
regimen complexity did not predict physical health-related quality of life

(β = -.081, p

=.387). A multiple regression was then conducted adjusting for age, gender, education,
race, ethnicity, marital status and cognitive status. After adjusting for the covariates,
medication regimen complexity did not predict physical health-related quality of life (β =
-.074, p = .458) (see Table 4.8).
H3b: Medication regimen complexity will be associated with mental healthrelated quality of life in older adults receiving community-based LTSS.
A Pearson product-moment correlation was calculated to explore the relationship
between medication regimen complexity (M = 20.6) and mental health-related quality of
life (MCS-12) (M = 47.3). This analysis found that there was a non-significant
correlation, r = -.076, p >.05, between the medication regimen complexity and mental
health-related quality of life.
A simple linear regression was performed before adjusting for age, gender,
education, race, ethnicity, marital status and cognitive status. Medication regimen
complexity did not predict mental health-related quality of life (β = -.076, p = .416). A
multiple regression was then conducted adjusting for age, gender, education, race,
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ethnicity, marital status and cognitive status. Medication regimen complexity did not
predict mental health-related quality of life (β = -.008, p = .938) (see Table 4.9).
Ancillary Analysis
Medication-related variables and Health-related quality of life
To further explore the relationships among the independent variables (total
number of active medications, number of therapeutic drug classes, and medication
regimen complexity) the study covariates (age, gender, education, race, ethnicity, marital
status and cognitive status) and the dependent variables (physical and mental healthrelated quality of life) multiple regression, using a fully adjusted model, was conducted
for physical (see Table 4.8) and mental health-related quality of life (see Table 4.9).
Physical Health-related quality of life. A summary of the regression
coefficients is presented in Table 11 and indicated that the number of total active
medications remained significant in predicting physical health-related quality of life (β =
-.497, p = .012), while the number of therapeutic drug classes (β = .156, p = .266) and
medication regimen complexity (β = .234, p = .189) were not associated with physical
health-related quality of life after controlling for age, gender, education, race, ethnicity,
marital status and cognitive status.
Mental health-related quality of life. Regression results (see Table 12) indicate
the overall model was not significant, F(10,105) = 1.182, p = .311. A summary of the
regression coefficients is presented in Table 12 and indicates the total number of active
medications (β = .001, p = .996), the number of therapeutic drug classes (β = -.190, p =
.172) and medication regimen complexity (β = .118, p = .504) were not associated with
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mental health-related quality of life after adjusting for age, gender, education, race,
ethnicity, marital status and cognitive status.
Study Variables and the Demographic Data
As a final step, attention was focused on the role of the demographic data in
relation to the study variables. Differences in the means were examined for demographic
characteristics and the study variables. The demographic factors included age, gender,
education, race, ethnicity, martial and cognitive status. Both significant and nonsignificant results were reported for selected variables.
Health-related quality of life and age. A one-way between-groups analysis of
variance (ANOVA) was conducted to explore the impact of age on health-related quality
of life based on the mean scores for physical (PCS-12) and mental (MCS-12) (see Table
9). Subjects were divided into three approximately equal groups according to their age
(Group 1: ≤75 yrs, n = 41, Group 2: 76-83 yrs, n = 37, Group 3: ≥84 yrs, n = 39). Equal
variances, as noted by non-significant (p > .05) Levene’s test of Homogeneity were
present for both PCS-12 and MCS-12 analysis. There was no statistically significant
differences in the PCS-12 mean scores across the three age groups: F(2, 114) = .074, p >
.05. In addition, there was no statistically significant difference in the mean MCS-12
scores: F(2, 114) = 2.81, p > .05.
Health-related quality of life and gender. An independent-samples t-test was
conducted to compare health-related quality of life physical (PCS-12) and mental (MCS12) scores for females and males in the study subjects. There was no significant
difference in PCS-12 scores for females (M= 30.8, S.D = 7.6) and males (M= 32.6, S.D =
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7.6; t (115) = -1.1, p =.27, two-tailed). The magnitude of the differences in the means
(mean difference = -1.78, 95% CI:-4.99 to 1.42) was small (eta squared = .01) according
to Cohen's (1988) guidelines. There was no significant difference in the MCS-12 scores
for females (M =46.9, S.D = 10.5) and males (M = 48.3, S.D = 10.54; t(115) = -.608, p =
.54, two-tailed). The magnitude of the differences in the means (mean difference = -1.3,
95% CI: -5.7 to 3.07) was very small (eta squared = .003).
Health-related quality of life and ethnicity. An independent-samples t-test was
conducted to compare health-related quality of life physical (PCS-12) and mental (MCS12) scores for Hispanic and non-Hispanic study subjects. There was no significant
difference in PCS-12 scores for Hispanics (M= 31.2, S.D = 7.1) and non-Hispanics (M=
31.2, S.D = 9.1; t (115) = -.019, p =.98, two-tailed). The magnitude of the differences in
the means (mean difference = -.021, 95% CI:-3.13 to 3.07) was very small (eta squared =
.001) according to Cohen's (1988) guidelines. There was no significant difference in
MCS-12 scores for Hispanics (M =47.6, S.D = 10.4) and non-Hispanics (M = 46.6, S.D =
10.9; t(115) = .468, p = .64, two-tailed). The magnitude of the differences in the means
(mean difference = 1.0, 95% CI: -3.2 to 5.2) was very small (eta squared = .003).
Medication-Related Variables and Age
Medication Regimen Complexity Index and Age. An ANOVA was conducted
to explore the impact of age on medication regimen complexity as measured by the
MRCI tool. Subjects were divided into three groups according to age (Group 1: ≤75 yrs,
n = 41, Group 2: 76-83 yrs, n = 37, Group 3: ≥84 yrs, n = 39). The results revealed
statistically significant mean differences in medication complexity based on age, F (2,
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120) = 3.419, p = .036. All groups were close to but not equal in numbers and ranged
from n = 37 (76 – 83 yrs) to n = 41 (≤ 75 years). When cell size are unequal, at test of
homoegeneity should be confirmed (Polit & Beck, 2012). Equal variances, as noted by
non-significant (p > .068) Levene’s test of Homogeneity of Variances were present. The
difference in the mean scores approached a moderate effect based on Cohen’s (1988)
classification terms of effect size. The effect size, calculated using eta squared, was .05.
Post hoc comparisons (Tukey) indicated that the mean score for Group 1 (M = 22.9, S.D
10.5) was statistically significantly different (p <.05) from Group 3 (M =16.9, S.D = 8.2).
Group 2 (M =22.2, S.D =14.8) did not differ significantly from either Group 1 or 3.
Summary of Results
In this chapter, a demographic analysis of the sample characteristics and
descriptive statistics for all independent and dependent study variables were discussed.
Main analysis of the research hypotheses revealed that the total number of medications
was predictive of physical health-related quality of life. This finding indicates that for
every unit increase in medication, physical health-related quality of life decreases by .5,
interpreted to mean that people taking more medications will have a decrease in physical
health-related quality of life. Simple regression analyses revealed that therapeutic drug
class and medication regimen complexity were not associated with physical healthrelated quality of life. In addition, multiple regression analysis revealed that the total
number of active medications, therapeutic drug class and medication complexity were not
associated with mental health related quality of life.
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Analysis of variance (ANOVA) revealed that mean medication regimen
complexity scores were significantly different based on age. Younger adults (aged 75
years or younger) had higher mean medication complexity scores on the MRCI than
adults aged 84 years and older.
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Table 4.8
Regression of Total Number of Active Medications, Number of
Therapeutic Drug Classes, and Medication Regimen Complexity Index on Physical
Health-Related Quality of Life in older adults receiving H&CBS in Washington Heights
and Inwood, NY, 2007-2008.
Unadjusted
Adjusted*
ß Coefficient
P value
ß Coefficient
P value
Total Active Medications
Total Active Meds
-.185
.046
-.186
.062
Age, years
-.041
.694
Gender, Female
.086
.399
Education, years
.087
.436
Race, White
.031
.756
Ethnicity, Hispanic
-.047
.665
Marital Status
.085
.417
Cognitive Status
.015
.890
Number of Therapeutic Drug Class (TDC)
TDC
-.046
.623
-.044
.651
Age, years
-.008
.937
Gender, Female
.115
.262
Education, years
.097
.389
Race, White
.458
.648
Ethnicity, Hispanic
-.055
.622
Marital Status
.081
.447
Cognitive Status
-.001
.992
Medication Regimen Complexity Index (MRCI)
MRCI
-.081
.387
-.074
.458
Age, years
-.020
.851
Gender, Female
.110
.283
Education, years
.092
.416
Race, White
.041
.678
Ethnicity, Hispanic
-.060
.585
Marital Status
.085
.424
Cognitive Status
-.002
.983
Total Active Medications, Total Number of TDC, MRCI
Total Active Meds
-.497
.012
TDC
.156
.266
MRCI
.234
.189
Age, years
-.021
.841
Gender, Female
.069
.497
Education, years
.083
.756
Race, White
.020
.840
Ethnicity, Hispanic
-.046
.673
Marital Status
.101
.335
Cognitive Status
.032
.764
Note. * Adjusted for all variables listed. TDC = Therapeutic Drug Class. MRCI =
Medication Regimen Complexity Index
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Table 4.9
Regression of Total Number of Active Medications, Number of
Therapeutic Drug Class, and Medication Regimen Complexity Index on Mental HealthRelated Quality of Life in older adults receiving H&CBS in Washington Heights and
Inwood, NY, 2007-2008.
Unadjusted
Adjusted*
ß Coefficient P value
ß Coefficient
P value
Total Number of Active Medications
Total Active Meds
-.101
.279
-.041
.676
Age, years
.264
.012
Gender, Female
.058
.562
Education, years
.119
.279
Race, White
.048
.621
Ethnicity, Hispanic
-.152
.159
Marital Status
.068
.507
Cognitive Status
.041
.701
Number of Therapeutic Drug Classes (TDC)
TDC
-.157
.091
-.114
.230
Age, years
.253
.014
Gender, Female
.057
.563
Education, years
.122
.261
Race, White
.051
.598
Ethnicity, Hispanic
-.140
.194
Marital Status
.057
.577
Cognitive Status
.043
.680
Medication Regimen Complexity (MRCI)
MRCI
-.076
.416
-.008
.938
Age, years
.271
.011
Gender, Female
.064
.518
Education, years
.121
.272
Race, White
.051
.601
Ethnicity, Hispanic
-.155
.151
Marital Status
.068
.507
Cognitive Status
.037
.727
Total Active Medications, Number of TDC, MRCI
Total Active Meds
.001
.996
TDC
-.190
.172
MRCI
.118
.504
Age, years
.271
.011
Gender, Female
.064
.522
Education, years
.131
.233
Race, White
.058
.555
Ethnicity, Hispanic
-.131
.231
Marital Status
.051
.624
Cognitive Status
.045
.670
Note. *Adjusted for all variables listed. TDC = Therapeutic Drug Class. MRCI =
Medication Regimen Complexity Index.
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Chapter V
Discussion

This chapter discussed the results of this study based on: (a) the six research
hypotheses within the context of findings and related literature, (b) integration of the
theoretical rationale, (c) study sample characteristics, (d) ancillary findings, and (e) a
review of the strengths and limitations of the research.

Overview of the Study
Medication regimens for each subject were examined in detail. Regression
analysis, controlling for age, gender, education, race, ethnicity, marital status and
cognitive status, determined that the number of active medications was a key predictor of
physical health-related quality of life but was not associated with mental health-related
quality of life. Therapeutic drug class and medication regimen complexity were not
associated with either physical or mental health-related quality of life. This was the first
study that explored these medication-related independent variables together in the context
of health-related quality of life within a community-dwelling, minority older adult
population receiving long-term services and supports.
First Hypotheses (H1a and H1b)
This study hypothesized that the number of active medications would be
associated with physical and mental health-related quality of life before and after
controlling for age, gender, education, race, ethnicity, marital status and cognitive status.
The data from the study determined that the number of active medications predicted
physical health-related quality of life before controlling for the covariates and remained
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significant in a fully adjusted model. For every unit increase in the number of active
medications, physical health-related quality of life decreases by 0.5. In other words, older
adults who take more medications have a decrease in physical health-related quality of
life. The number of active medications was not associated with mental health-related
quality of life before or after controlling for covariates.
The National Center for Health Statistics (NCHS) (2010) reported trends in
prescription drug use continue to increase among older adults (aged 60 and over) with
88% using at least one prescription drug per day. More than 76% use two or more
prescription drugs and 37% use five or more. 17% of men and 19% of women use at least
ten medications on a regular basis (Slone Survey, 2006). Overall women use more
prescription drugs than men and non-Hispanic whites have the highest prescription drug
use when compared the Mexican-American population who have the lowest utilization
(NCHS, 2010). Comparatively, the data from this study indicated the average number of
medications was 9.3 with a range from 2 to 19. Females used an average of 9.6
medications and males used an average of 8.2. Hispanics used an average of 9.2
medications and non-Hispanics used an average of 9.3. The results indicate a higher
degree of medication use when compared to the national data for age, gender and
ethnicity.
The use of multiple medications, also known as polypharmacy, in older adults has
been widely recognized in several studies to increase drug related problems affecting
patient safety (Elliot et al., 2013; Institute of Medicine [IOM], 2006; Liu, Manias, &
Gerdtz, 2010), quality of care (American Geriatrics Society [AGS], 2012a; AGS, 2012b;
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Roth et al., 2009), decline in functional status, avoidable hospitalizations and increased
health-care costs (Budnitz et al., 2011; Slabaugh et al., 2010; Tinetti et al., 2014).
Yet gaps exist as few studies have explored the relationships of multiple medication use
and health-related quality of life in community-dwelling older adults. There were no
studies found that examined medication regimens of community-dwelling minority older
adults to the level of detail conducted in this study. The findings of the current study
support others showing that the number of medications used in older adults was a
significant predictor of physical health-related quality of life.
Francic & Jiang (2006) investigated the relationship between potentially
inappropriate medication use and two generic health-related quality of life measures, the
SF-12 and EuroQol’s EQ-5D. Using a longitudinal retrospective cohort design, the
researchers conducted secondary analysis of adults 65 years of age and older who were
part of the national 1996 Medical Expenditure Panel Survey (MEPS). The study found
that the number of drugs prescribed was a significant predictor of health-related quality
of life for PCS-12 (r= -.237) and EQ-5D VAS (r = -.361) which indicated that a higher
number of prescribed medications predicted poor physical health-related quality of life.
Additionally, a large study (N = 1099) using secondary analysis from the
Consumer Assessment Study included frail community-based older adults with an age
range from 60 to 106 years of age, 73% female and 80% White (Classen, Mann, Wu, &
Tomita, 2004). The study examined the relationship between the number of medications
and functional status, and health-related quality of life. The average number of
medications was 5.4 (S.D 3.8) from 13 different drug classes. Two global self-rated
quality of life questions were asked, but were lacking validity or reliability measurement
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data. The findings indicate that increased age, increase number of chronic diseases and
decrease in health were all associated with higher numbers of medications. The lack of
psychometric properties for the health and quality of life questions were of concern in
this study. The average number of medications was lower (5.4) compared to the current
study (9.3).
In two smaller cross-sectional studies, findings indicated significant associations
between polypharmacy and physical health-related quality of life. Sorensen et al. (2005)
reported poor patient outcomes to include decrease in physical health-related quality of
life in community-based study of older adults (N = 204) living in Australia. The sample
average age was 72.4 years and 61% female. Patients self-reported taking on average of
9.9 medications during office visits. When home visits were conducted by clinicians, the
average number of medications found in the home increased to14.7. Medication-related
risk factors identified included the total number of medications, having no established
routine for medication administration, recent reports of adverse drug events (ADE),
therapeutic duplications, hoarding medications, and lack of knowledge regarding brand
name versus generic. The medication-related factors related to decrease in physical
health-related quality of life (measured by the SF-36 PCS) and severity of illness
included an increased in number of medications (p<.001), recent ADEs and therapeutic
duplications.
Likewise, Henderson et al. (2006) examined the association of polypharmacy and
health-related quality of life in a small sample (N = 63) of community-dwelling American
Indians aged 50 years and older. The average number of medications was 9.8 for males
and 10 for females with a range from 4 to 19. Health related quality of life was measured
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by the MOS SF-36 PCS and MCS scores. The PCS score (r= -.91, p=.045) was
associated with the degree of polypharmacy before and after controlling for age, gender
and chronic disease. The current study is similar in the average number and range of
medications, although the demographic characteristics differ in age and ethnicity.
Cleary & Howell (2007) examined prescription drug use and health-related
quality of life in rural adults aged 65 years and older (N =43). The sample was 98%
White with an average age of 78 years. The mean number of medications was 3.6 Health
related quality of life was measured by the SF-36 PCS and MCS scores. The study found
no significant association between PCS and MCS and the number of medications.
The existing research suggests that older adults who take more medication have a
decrease in physical health-related quality of life. Research specifically examining the
relationships between medication use and health-related quality of life among
predominately Hispanic older adults has not been widely studied. The findings of this
study support current evidence and expand the demographics with the inclusion of an
ethnic population (68% Hispanic). This study strengthens the evidence regarding the
potential negative impact of multiple medication use can have in older adults.
Second Hypotheses (H2a and H2b)
It was hypothesized that the number of therapeutic drug classes would be
associated with physical and mental health-related quality of life before and after
controlling for age, gender, education, race, ethnicity, marital status and cognitive status.
The data suggested that the number of therapeutic drug classes was not associated with
either physical or mental health-related quality of life before and after controlling for the
covariates.
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The majority of literature investigating therapeutic drug classes is related to the
risk of adverse drug events as a result of specific drug classes. Several studies support the
contribution of specific drug classes to increase risk of falls (Tinetti et al., 2014),
confusion, and adverse drug events (AGS, 2012a; Choudry et al., 2011). Many
preventable adverse drug events are associated with cardiovascular drugs, non-opioid
analgesics, hypoglycemic agents, anticoagulants, and opioids (Bopari & Korc-Grodzicki,
2011; Gurwitz et al., 2003). Budnitz et al. (2011) found adults aged 65 years and older
were admitted for emergency hospitalizations as result of four common medications and
medication classes taken either alone or combination: warfarin (33.3%), insulins (13.9%)
oral anti-platelet agents (13.3%) and oral hypoglycemic agents (10.7%). Hospitalizations
resulting from hematologic agents were for acute hemorrhages (71.3%) and almost all
hospitalizations due endocrine agents were a result of hypoglycemia (94.6%).
Some studies have explored the relationship of specific drugs or drug classes and
health related quality of life in community-dwelling older adults aged 65 years and older
including: treatment of high cholesterol with cholesterol lowering drugs (Carlsson,
Papcke-Benson, Carnes, McBride, & Stein, 2002), and older and younger adults with
insulin-treated diabetes (Trief, Wade, Pine, & Weinstock, 2003). Carlsson et al. (2002)
used a double-blind RCT design in a small sample (N =41) and measured the Global
Health Perception Question. Findings determined health-related quality of life scores did
not change after 12 months of therapy with cholesterol lower agents. Trief et al. (2003)
examined health-related quality of life measured by the SF-36 PCS and MCS scores and
found when compared to a younger cohort, older adults with insulin-treated diabetes
encountered more decline in physical health-related quality of life, but revealed higher
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mental health-related quality of life with better coping and social supports that may
account for reduced levels of distress related to diabetes.
Holt et al. (2010) examined health-related quality of life and antihypertensive
medication adherence in a large cohort (N = 2,180) of community-dwelling older adults
aged 65 and older. The average age of the participants was aged 75 years, 70% were
white, 58.5% were women and 14% had low medication adherence. Health-related
quality of life was measured using the MOS SF-36 tool. Lower physical and mental
health-related quality of life was associated with decreased antihypertensive adherence.
The most frequently prescribed medications used by American older adults, aged
60 and over, are cardiovascular agents to treat high blood pressure, heart disease and high
cholesterol including: (a) diuretics 19.9%, (b) beta-blockers 26.4%, and (c) cholesterollowering drugs 44.9% (NCHS, 2010). The fact that close to 40% of older Americans use
five or more medications a day reflects the degree of co-morbidity that regularly occurs
in this age group. Qato et al. (2008) determined community-dwelling older adults are the
largest consumers of prescription and over the counter medications along with dietary
supplements, which are often all used concurrently. As a result, an estimated 1 in 25 older
adults are at risk for significant drug to drug interactions.
This study determined the average number of therapeutic drug classes was 4.89
with a range from 2 to 8. The five most frequently used drug classes were: cardiovascular
agents (97%), central nervous system agents (94%), nutrients and nutritional agents
(63%), gastrointestinal (60%) and endocrine and metabolic agents (59%). These findings
are similar to what is described in the literature and expands the types of therapeutic drug
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classes most frequently used in older adults receiving home and community-based
services.
Third Hypotheses (H3a and H3b)
It was hypothesized that medication regimen complexity would be associated with
physical and mental health-related quality of life before and after controlling for age,
gender, education, race, ethnicity, marital status and cognitive status. The data suggested
that medication regimen complexity was not associated with either physical or mental
health-related quality of life before and after controlling for the covariates. Medication
regimen complexity data revealed an average total score of 20.6 with a range from 3 to
69. The greatest contributor to the MRCI total score was dosing frequency with an
average score of 13.4 and a range from 2 to 38. The results support similar findings for
mean MRCI scores in a similar population (McDonald, et al., 2012).
Medication regimen complexity measurement is an emerging area of interest and
research including: predictive risk for hospitalization and readmission (Elliott,
O’Callaghan, Paul, & George, 2013; Willson, Greer, & Weeks, 2014), chronic disease
management (Libby et al., 2013; Rettig, Wood, & Hirsch, 2013), medication adherence
(Choudry et al., 2011;Witticke, Seidling, Lohmann, Send, & Haefeli, 2013), patient
preference (Witticke, Seidling, Klimm, & Haefeli, 2012), and decision support
technology (McDonald et al., 2012).
Although medication regimen complexity was not associated with either physical
or mental health-related quality of life, this study advances the use of MRCI tool in
community-dwelling older adults, which has not been widely studied in home care
populations. In addition to assessing the total number of medications, quantifying the
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medication regimen provides a more nuanced way of determining potential challenges
and risks associated with complex regimens in community-dwelling older adults
(McDonald et al., 2012).
Theoretical Rationale
Wilson and Cleary’s (1995) health-related quality of life conceptual model
provided the theoretical framework for this interpretation (see Figure 1). This study
examined components of health-related quality of life by testing Wilson and Cleary’s
model in community-dwelling older adults who were receiving long-term services and
supports. According to the Wilson and Cleary model, measures of health exist along a
continuum moving from biological measures at one end of the continuum to overall
quality of life at the other, and theorizes bidirectional relationships among the domains.
The Wilson and Cleary model distinguishes components of health-related quality of life
from a conceptual standpoint within five domains (biological and physiological factors,
symptom status, functional status, general health perceptions, and overall quality of life).
Moving in the model from left to right, the domains of each level become more complex
for the clinician to determine and measure. The “inputs” as the model progresses, are
often not within the control of the clinician or health care system (patient preference, role
of emotional or psychological factors) (Wilson & Cleary, 1995, p.63). The characteristics
of the individual and the environment are overarching factors that affect all five domains.
Individual characteristics commonly associated with illness are age, gender, race,
ethnicity and marital status (Ferrans et al., 2005). This study proposed to test the
theoretical linkages of the model components to include: biological and physiological
factors (medication-related factors: number of medications, number of therapeutic
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classes, and medication regimen complexity) and overall quality of life (MOS SF-12
PCS-12 and MCS-12). Individual characteristics selected for inclusion were: (a) age, (b)
gender, (c) education, (d) race, (e) ethnicity, (f) marital status and (g) cognitive status.
Regression analysis determined that the number of active medications were predictive of
physical health-related quality of life before and after controlling for individual
characteristics (age, gender, education, race, ethnicity, marital status and cognitive
status). Individuals who take more medications have a decrease in physical health-related
quality of life. None of the medication-related factors were associated with mental healthrelated quality of life before or after controlling for individual characteristics (age,
gender, education, race, ethnicity, marital status and cognitive status).
Study Sample Characteristics
Significant risk factors, based on demographic characteristics, have been
associated with medication safety in older adults who are aged 65 years and older, have
less than a high school education, a minority, non-English speaking, have low incomes or
are unemployed (Health Research & Education Trust, Institute for Safe Medication
Practices, and Medical Management Association [HRET, ISMP, & MGMA], 2008;
Lindenberg, 2010). The study sample reflected several of these risk factors to include: (a)
an average age of 79 years, with a range from 63 to 97 years, (b) 59% eighth grade
education or less (n = 72), (c) 68% (n = 84) Hispanic, 35% Black or African American (n
=35).
Ancillary Analysis
Differences in the level of medication complexity based on age were reported.
Older adults aged 84 years and older demonstrated less medication complexity when
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compared with adults aged 75 years and younger. These differences may be as a result of
having chronic illness at a younger age with greater severity of illness that requires more
medications. In addition, goals of care may shift from aggressive, curative management
towards an approach of comfort and palliation interventions requiring decreased
medication use.

Additional analysis was conducted to determine whether there were significant
differences in demographic data related to the main study variables. There were no
significant differences in either physical or mental health-related quality for age, gender
or ethnicity. There were no significant differences in the total number of medications,
therapeutic drug classes, or medication complexity for gender and ethnicity.
Strengths and Limitations of this Study
This was the first study to examine three medication-related variables, the number
of active medications, the number of therapeutic drug classes, and medication regimen
complexity and the association of health-related quality of life in a population at risk for
potential medication-related issues. The findings from this study contributed to healthrelated quality of life research in older adults with long-term health needs. In addition, it
expanded the growing body of research related to medication regimen complexity
measurement with strong inter-rater reliability and relevance to clinical practice for
patients receiving home-based care. The use of secondary data facilitates the generation
of new knowledge maximizing existing data and is both economical and efficient.
Limitations

MEDICATION COMPLEXITY AND HRQOL

77

The sample size was small, predominately female (75%), Hispanic (68%), in one
urban setting which makes it difficult to generalize the findings. Use of secondary
analysis presents limitations because variables and instruments are defined by the
primary study. Additional collection of medication data required re-identification of the
dataset. Cross sectional design allows measurement of variables at a single point in time
but does not allow for analysis of direction of associations or changes over time.
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Chapter VI
Implications, Recommendations and Conclusions

Evidence is limited to date linking medication-related variables to include taking
multiple medications, using multiple therapeutic drug classes and complex medication
regimens in older adults. There is scant research regarding these characteristics and their
relationship to health-related quality of life. Findings from this study determined that the
use of multiple medications was associated with a decreased physical health-related
quality of life in older adults receiving home and community-based services. Several
studies have identified community-based older adults as the highest consumers of
medications and as a result are at higher risk for poor health outcomes that are
medication-related. Community health nurses can play a significant role in helping
patients manage complex medication regimens, and reduce potential drug related
problems to include simplifying medications. Home visits are critical when determining
specific medication related risk factors may be exist that are not apparent based on patient
self–reporting alone (Sorensen et al., 2005).
Implications
The findings from this study generated several implications for nursing practice
and education. Additionally, recommendations in the arenas of public policy and future
research are elucidated from this research.

Nursing Practice Implications
Health plays a central role in nursing and is one of the key metaparadigm
components (Sousa & Williamson, 2003). Evaluating health-related quality of life in
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older adults should be embedded as a standard of nursing practice. Identifying the health
needs of older adults improves understanding of their responses to disease states as well
as to prescribed treatments including medications and the impact that disease and medical
treatments have on daily life activities from the perspective of the individual, rather than
the nurse. Incorporating health-related quality of life assessment into clinical practice
provides greater understanding of patients' responses and their self-perception of health to
include the impact of taking multiple medications (Borglin et al., 2005; Guyatt, et al.,
2007; Singh & Dixit, 2010; Sousa & Williamson, 2003).
Community Health Nursing. Plain and simple, caring for older adults who wish
to remain in their own home, but require long term services and supports (LTSS) to do
so, is complex and challenging on several levels. Understanding the current LTSS
landscape and future growth and demand for these services (as a result of the “Baby
Boomer” generation growing older), is a call to action for nursing, but significantly so for
nurses who provide and manage care for older adults in community-based settings. The
fact that 89% of Americans aged 50 years and older want to remain in their own homes
for as long as possible and an estimated 5 million older adults are in need of this level of
care (AARP Public Policy Institute, 2011) posits nursing care in communities in a crucial
position. Community health nurses (CHNs) can develop, provide and improve care that is
patient-centric, high quality and cost efficient for older adults who often have complex
clinical and psychosocially needs often compounded by polypharmacy and medication
regimen complexity.
Community health nurses (CHNs) play a significant role in helping patients
manage complex medication regimens, and in particular those patients with chronic long-
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term needs that require long term service and supports who wish to remain at home
(IOM, 2010). A key driver for nursing home admissions is the often the inability to self
manage complex medication regimens.
There are several implications for CHNs that may reduce medication complexity
and decrease the risk for adverse drug events with the potential to improve a patient’s
health related quality to include:


A first step in reducing medication regimen complexity is to identify patients with
medication complexity. The ability for clinicians to easily identify complex
medication regimens through the use clinical support tools such as the MRCI tool
has not been widely studied in home-based settings. This study advanced the use
of MRCI tool in home care setting looking at older adults with chronic illness



The use of a paper-based MRCI tool is not pragmatic in a community-based
setting; the development of an electronic MRCI tool would be optimal for practice
settings (McDonald et al., 2012)



Employ the use of medication simplification using a stepwise approach. This
process involves a thoughtful approach to reducing and simplifying medications
to include: a) using long-acting forms of medication, b) use of one pharmacy
provider, c) discard old or discontinued medications, d) provide alternatives to
medication therapy, e) decrease the use of multiple drug treatment for a single
condition, f) discontinue or reduce medication whenever possible, and g) schedule
medications times with daily routines (e.g. brushing teeth, eating a meal) (Home
Health Quality Improvement Campaign, 2007)

MEDICATION COMPLEXITY AND HRQOL



81

Fostering inter-professional partnerships with multiple disciplines to include
medical providers, community pharmacists, social workers, nutritionists, physical
therapists with a focus for improved communication regarding medication
management and best practice



Consideration and assessment of older adults preference for treatment choice, in
particular those patients with multiple conditions (co-morbidities); identify the
patient’s goals of care and align treatment accordingly



Explore patient experiences regarding their medication regimens. Providing an
environment to allow patients to share their perceptions about their medications
enhances a patient-centered approach to care from the patient’s perspective



Identify and administer a health-related quality of life measurement tool as part
of nursing assessment at regular intervals to measure change over time and
determine precipitating event of decline

Advanced Practice Nursing. Home-based primary care services provided to
community-dwelling older adults by Nurse Practitioners (NPs) is an area with significant
potential to improve care. By assessing health-related quality of life and medication use,
NPs practicing in full scope can work with older adults to establish patient-centric plans
of care that reflect optimum use of therapeutic agents while minimizing harm and
improving health-related quality of life. NPs can ‘unpack’ the different complex layers
of medication regimens by using a comprehensive approach when assessing the quality of
medication use in community-dwelling older adults. By using evidence-based practice,
NPs ensure the rational use of medications that are appropriate based on individual
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clinical needs in doses that are therapeutic and by simplifying the medication regimen to
minimize risk and reduce adverse events and ultimately improve health-related quality of
life outcomes (George & Jacobs, 2011; Lindenberg, 2010; World Health Organization,
2010). NPs are well situated to better understand the burden an older adult may
experience when taking multiple medications at varied times with different requirements
and how this burden affects their day-to-day routine such as increased urination,
bothersome side effects and the overall impact on their health-related quality of life.
Identifying ways to develop and support greater access to NP-led primary care for this
population needs enhancement. Since the number of active medications was the only
predictor of physical health-related quality of life, it is imperative to ensure that older
adults are the taking the absolute minimum number of medications needed to maintain
health.
Enhancing Patient-Centered Care. Understanding the patient’s perspective and
their preferences regarding medication-related factors to include the number of
medications and the frequency they require is an important implication from this study.
The use of medication should begin with shared-decision making process between the
patient and the prescriber based on the individual’s preferences and goals of care. Nurses
practicing in home and community-based settings have an ideal opportunity to educate
and empower patients to become active participants in their care to include reducing the
number of medications at less frequent intervals.

Public Policy Implications
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Long Term Services and Supports. The cost of LTSS is expensive for all levels
of care to include nursing homes, assisted living facilities, and home community-based
care services (HCBS) (Kaiser Commission on Medicaid & the Uninsured, 2013). LTSS is
primarily funded by Medicaid with 73% of the costs spent on LTSS provided in nursing
homes, the most expensive level of LTSS, while only 27% is spent in HCBS, which is the
least expensive level of LTSS (AARP Public Policy Institute, 2009). Public policy reform
need to continue to support the expansion HCBS LTSS options that provide patientcentric quality care that is cost efficient.
Future Research Recommendations

As a result of advances in medical science, many older Americans are living
longer with chronic conditions including heart disease, diabetes and asthma. Many
chronic conditions require long-term medication management and as a result, the focus
on health-related quality of life will become an increasingly important outcome measure.
Determining predictors of health-related quality of life, and in particular identifying
predictors that may be modifiable (e.g. reducing the number of daily medications) to
improve health-related quality of life need further investigation. Further research is
required to identify methods to translate health-related quality of life measures into useful
clinical decision support tools to include a focus on the patient’s perceptions of treatment.
The recommendations for future research are as follows:



Conduct a qualitative study to explore patient preference for medication regimen
characteristics in a sample with characteristics similar to this study sample. The
aim would be to explore how patients relate their health and use of medication to
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include the use of alternative treatments to include folk medicine and
complementary and alternative medicine (CAM).


Develop clinical guidelines for older adults with multiple co-morbidities
particularly in the presence of cognitive impairment aimed at simplifying
regimens rather than complicating them (American Geriatrics Society, 2012a;
2012b; Boyd et al., 2005)



Hold providers accountable to practice rationale prescribing. Use of rational
prescribing (Crigger & Holcomb, 2008; Lindenberg, 2010) guides clinicians to
provide individuals with the appropriate medications to meet their clinical needs,
at the minimal required doses for the shortest duration possible, provided at the
lowest costs available



Develop automated MRCI and health-related quality of life clinical decision
support tools that can be standardized for use across multiple health-care settings
shared among multiple providers

Conclusions
Evaluation of medication use is evolving from simply counting the number of
drugs to more precise medication-related factors such as therapeutic drug class, evidence
of therapeutic effects and the degree of regimen complexity (Gnjidic et al., 2013). Older
adults experience significantly higher rates of adverse drug events (ADRs) and as a result
experience higher rates adverse outcomes to include falls, hospitalizations, delirium, and
functional decline (Tinetti et al., 2014). As a result, health-related quality will often
decline as well (Henderson et al., 2005; Sorensen et al., 2005). This study contributed to
the evidence of medication use and health-related quality of life in older adults.0
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Appendix F
Therapeutic Drug Classification Tool
Therapeutic Drug Class

Medication Name (Brand)
(Example)

Medication Name
(Generic)
(Example)

1.Cardiovascular

Digoxin

Lanoxin

2. Central Nervous System

Amitriptyline

Elavil

3. Endocrine & Metabolic

Metformin

Glucophage

4. Systemic Anti-Infective

Levofloxacin

Levaquin

5. Respiratory

Albuterol

Proventil

6. Hematologic

Clopidogrel

Plavix

7. Gastrointestinal

Ranitidine

Zantac

8. Renal & Genitourinary

Spironolactone

Aldactone

9. Dermatologic

Hydrocortisone

Hydrocort

10. Ophthalmic & Otic

Timolol 0.5%

Timoptic 0.5%

11. Biologic & Immunologic

Methotrexate

Rheumatrex

12. Nutrients & Nutritional

Calcium

Citracel

13. Other

Glucosamine Sulfate
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Appendix L
JAMA Copyright Permission for Wilson & Cleary’s HRQOL Conceptual Model Figure
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